

PCT/GB2004/003486



GB04/3486



INVESTOR IN PEOPLE

# **PRIORITY DOCUMENT**

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

REC'D 27 AUG 2004

WIPO


PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.




Signed

*Stephen Handley*

Dated

20 August 2004

Best Available Copy



# Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road  
Newport  
South Wales  
NP10 8QQ

1. Your reference 101162-1 GB

2. Patent application number  
(The Patent Office will fill in this part)

0319332.3

3. Full name, address and postcode of the or of each applicant (underline all surnames)

AstraZeneca AB  
SE-151 85 Sodertalje  
Sweden

Patents ADP number (If you know it)

7822448003

If the applicant is a corporate body, give the country/state of its incorporation

Sweden

4. Title of the invention

AMPLIFICATION

5. Name of your agent (If you have one)

BRYANT, Tracey

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

AstraZeneca UK Limited  
Global Intellectual Property  
Mereside, Alderley Park  
Macclesfield,  
Cheshire SK10 4TG

Patents ADP number (If you know it)

7822471002

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number  
(if you know it)

Date of filing  
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing  
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
  - b) there is an inventor who is not named as an applicant, or
  - c) any named applicant is a corporate body.
- See note (d))

# Patents Form 1/77

- 9 Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 75

Claim(s) 11

Abstract

Drawing(s) 14 + 14 *ll*

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination (*Patents Form 10/77*)

Any other documents  
(*please specify*)

8 pages of Sequence Listing

11. I/We request the grant of a patent on the basis of this application.

Signature

Date

*Kevin Bill*

15/8/83

12. Name and daytime telephone number of person to contact in the United Kingdom

Kevin Bill - 01625 512461

## Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

## Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

## AMPLIFICATION

### FIELD OF THE INVENTION

The present invention relates generally to the field of recombinant DNA technology.

5 In particular, the present invention relates to improved methods for producing amplified heterogeneous populations of RNA from limited quantities of starting RNA.

### 10 BACKGROUND TO THE INVENTION

The field of gene expression profiling has exploded in the last few years, and can now be performed on a genome wide scale. Identification of differentially expressed genes is being used for medical, clinical, and biological research to help understand the molecular mechanisms that underlie biological processes including disease -  
15 such as tumourigenesis - differentiation and development. Gene expression profiling can be used across a broad range of applications, for example for the identification of novel targets for therapeutic intervention, identification of potential diagnostic and prognostic markers, to help understand clinical response to drugs and outcome, and identify toxicological responses. DNA arrays of immobilised gene-specific  
20 sequences (probes) on a variety of platforms - such as macroarrays, microarrays or high-density oligonucleotide arrays - on different solid supports (e.g., nylon membranes, glass slides or silicon/ceramic chips) are widely applicable in different areas of genomics research.

25 The most commonly used mechanism for RNA amplification is a T7 based linear amplification method first developed by Van Gelder *et al* (1990), Eberwine *et al* (1992) and Philips and Eberwine (1996), and is described in US 6,291,170, US 5,891,636, US 5,716,785, and US 5,545,522. In this procedure, a synthetic poly(dT) primer containing the phage T7 RNA polymerase promoter is used to prime  
30 synthesis of first strand cDNA by reverse transcription. Second strand cDNA is synthesised by limited RNase H digestion, followed by second strand synthesis with *E. coli* DNA polymerase I. Amplified antisense RNA (aRNA) is obtained from *in*



*vitro* transcription of the double-stranded cDNA template using T7 RNA polymerase.

This procedure is the basis for Affymetrix GeneChip oligonucleotide arrays where  
5 biotinylated ribonucleotides are incorporated into the aRNA, also known as  
complementary RNA or (see Affymetrix GeneChip ® Expression Analysis  
Technical Manual, and Mahadevappa and Warrington (1999)), and is also the basis  
for glass microarrays (Pabón *et al*, (2001)).

10 Although this method involves an amplification step with T7 RNA polymerase, it is  
typically used with 5-25µg total RNA. However, in order to obtain sufficient  
amounts of amplified RNA (aRNA) for microarray experiments, investigators have  
resorted to two or more rounds of cDNA synthesis coupled with T7 amplification to  
generate a representative mRNA profile and this has allowed them to combine  
15 microdissection with array technology (Luo *et al* (1999), Ohyama *et al* (2000),  
Affymetrix Technical Note GeneChip ® Eukaryotic Small sample Target Labelling  
Assay Version II, and Luzzi *et al* (2001)).

Wang *et al* (2000) have described a T7-based amplification protocol modified with a  
20 SMART<sup>TM</sup> template-switching primer that is used to theoretically generate a full-  
length double stranded cDNA. The fidelity of aRNA amplified was shown to be  
comparable between the expression profiles of 1:10000 to 1:100000 of commonly  
used input RNA, and those observed with conventional polyA+ RNA or total RNA.  
Hu and co-workers (2002) compared amplified and unamplified samples to evaluate  
25 a similar T7 based protocol with a template switching mechanism adopted from  
Wang *et al*. Their results showed concordance between amplified and non-amplified  
samples, and four expressed and two differentially expressed genes were verified  
using Northern and Western blotting and immunohistochemical assay.

30 Modifications of the T7-based amplification technology have also been used in two  
commercially available amplification kits. The RiboAmp<sup>TM</sup> RNA Amplification  
Kits (Arcturus) achieves high yields of amplified RNA with a proprietary linear  
amplification method. This method utilises one or two rounds of T7 based

amplification depending on the amounts of starting material. RealArt™ mRNA amplification kit (Artus GmbH) provides a T7 based amplification technology. mRNA is converted to cDNA with an anchored poly(dT) primer, and then second strand synthesis is performed using a proprietary "Box/randomized primer mix" which generates a random representation of the complete cDNA. The randomly primed cDNA is denatured and primed with a T7 promoter/poly(dT) primer. This leads to double stranded cDNA with a T7 promoter at one end that can be used as a template for *in vitro* transcription.

- 10 Polymerase chain reaction (PCR) is an extremely powerful technique for amplifying specific nucleic acid sequences as described in US 4,683,202 and US 4,683,195. PCR typically comprises treating separate complementary strands of a target DNA with two oligonucleotide primers to form complementary primer extension products on both strands that can act as templates for synthesising copies of the desired  
15 nucleic acid sequences. The separation and synthesis steps are repeated in an automated system using thermostable polymerases, essentially exponential duplication of the target sequences can be achieved.

Amplification of cDNA by PCR requires the presence of primer binding sites at both  
20 cDNA ends. These primer sites can be attached by a number of methods, including  
a) the addition of a homopolymer tail on the 3' end of the first-strand cDNA (Akowitz & Manuelidis, (1989), Belyavsky et al, (1989), Domec, et al (1990), and Brady, et al (1990)); b) ligation of single-stranded anchor oligonucleotide to the 3' end of the first-strand cDNA (Apte & Siebert, (1993)); c) ligation of single-stranded  
25 anchor oligonucleotide sequence to the 5' end of mRNA (Fromont-Racine *et al* (1993), Kato, *et al* (1994), Maruyama & Sugano, S. (1994)); d) ligation of double-stranded adaptors to the 5' end of the double-stranded cDNA (Frohman & Dush, (1988)); and e) addition of amplifier sequence at the 5' and 3' ends of single-stranded cDNA in the first strand synthesis reaction by a template switching  
30 mechanism (SMART™, Switching Mechanism At the 5' end of RNA Transcripts, BD Biosciences Clontech) as described in Chenchik *et al* (1998) and Zhu, *et al* (2001)). Template switching is also described in US 5,962,271 and US 5,962,272.

Amplification techniques based on reverse transcription polymerase chain reaction (RT-PCR) have been described for global amplification of mRNAs from single cells (Rappolee, *et al* (1989), Brady, *et al* (1990), Cheng, *et al* (1996), O'Brien, *et al* (1994)). PCR based approaches such as that described by Brady *et al* (1990) have also been employed to look at gene expression by global mRNA amplification followed by cDNA array analysis (Theilgaard-Monch, *et al* (2001)). However, this method is designed to limit the size of the first strand cDNA to about 300-700 bases, and so corresponding arrays have to be designed such that the arrayed clones contain the 3' ends of each cDNA.

10

Recently, a rapid and highly optimized global RT-PCR procedure has been described (Iscoe, *et al* (2002)) that is also based on methods described previously by Brady *et al* (1990). The procedure involves reverse transcription of a first cDNA strand primed by poly(dT), addition of an poly(dA) tail with terminal transferase, and subsequent exponential amplification using a single poly(dT)-containing primer. Reverse transcription is limited to only a few hundred bases of extreme 3' sequence by limiting deoxynucleotide concentrations and the time of the reaction. These conditions were intended to provide a more uniform likelihood of sampling individual mRNA transcripts and more uniform amplification efficiency across all cycles. This global RT-PCR approach preserved abundance relationships through amplification and yielded reproducible results from the picogram range of total RNA obtainable from single cells.

---

A PCR-based amplification method, three prime end amplification PCR (TPEA-PCR), has been developed which results in global amplification of the 3' end of all the mRNAs present in a sample (Dixon, *et al* (1998)). PCR amplification occurs between primers incorporated into the first strand cDNA during reverse transcription, and a second strand primer that has a partially degenerate 3' end and is designed to anneal once every kilobase.

30

Recently, another PCR-based amplification method "balanced PCR" was described by Makrigiorgos, *et al* (2002). Balanced PCR allows a balanced amplification of fragments from two complex DNAs even after three sequential rounds of PCR. Two

distinct genomic DNA or cDNA samples are tagged with oligonucleotides containing both a common and a unique DNA sequence. The samples are pooled and amplified in a single PCR tube using the common DNA tag, and therefore there should be no differences in amplification efficiency. The PCR-amplified pooled  
5 samples can be separated using the DNA tag unique to each individual genomic DNA sample. The principle of this method has been validated with synthetic DNA, genomic DNA, and cDNA applied on microarrays. By removing the bias of PCR, this balanced PCR approach should allow genetic analysis in minute laser-microdissected tissues, paraffin-embedded archived material, or single cells.  
10 However, routine use of this method for amplification of RNAs from biopsies has not yet been reported.

A PCR amplification method based on reverse transcription, followed by random PCR amplification of the cDNA and *in vitro* transcription of the resulting PCR  
15 product with T7 RNA polymerase has been described by Roche Applied Science in their Microarray Target Amplification kit (Cat No 3 310 191). In this procedure, nanogram quantities of total RNA are reverse transcribed into cDNA using a modified poly(dT) primer (TAS-T7 poly(dT)<sub>24</sub>). The unique Target Amplification Sequence (TAS) has no homology to any known human sequence, generates the 3'  
20 anchor on the cDNA for subsequent PCR amplification. The T7 promoter sequence is added to allow the generation of labelled cRNA targets by *in vitro* transcription. A TAS-(dN)<sub>10</sub> primer is used in order to include a 5' amplifier sequence on the cDNA and is used for the initiation of the second strand cDNA synthesis. PCR is then performed with TAS-primer and the optimal numbers of cycles have to be  
25 determined. PCR products are then purified and used for *in vitro* transcription.

SMART<sup>TM</sup> generated cDNA has been used for several applications including cDNA library construction, and as hybridisation probes for cDNA and oligonucleotide-based microarrays. SMART<sup>TM</sup> technology coupled with PCR has allowed the use of  
30 lower amounts of starting total RNA, although there is only limited data to support the usefulness of this technology in microarray analyses where it is important to maintain the mRNA representation [Spirin, *et al* (1999), Gonzales *et al* (1999),

Vernon, *et al* (2000), Livesey, *et al* (2000), Zhumabayeva, *et al*, (2001) and Fink, *et al* (2002)].

The limitation of these technologies is the requirement for relatively large amounts  
5 of intact total RNA. By way of example, typical microarray labelling procedures  
require 0.5–4 µg poly(A) + RNA or 5–50 µg total RNA per microarray. This  
amount of poly(A) + RNA or total RNA can be obtained from samples of tissue that  
weigh greater than 50–100 mg, however many samples are significantly less than  
this, for example many clinical biopsies. A recent pilot study by Assersohn *et al*  
10 (2002) showed that only 15% of fine needle aspirates (FNA) from human breast  
cancers produced sufficient mRNA for expression array analysis.

A simple and robust method that is not restricted by low efficiency and the use of  
multiple time consuming steps and allows amplification from small amounts of  
15 RNA, whilst maintaining sensitivity, reproducibility, and can effectively identify  
differentially expressed genes is highly desirable in the art.

#### SUMMARY ASPECTS OF THE PRESENT INVENTION

The present invention combines the use of template switching with nucleic acid  
20 amplification – such as PCR - to generate amplification products representative of an  
entire RNA population. An RNA polymerase promoter sequence allows  
transcription-based amplification to be performed on the derived amplification  
products such that antisense amplified RNA (aRNA) or complementary RNA  
(cRNA) is produced for subsequent downstream applications.

25

Advantageously, the RNA generated in accordance with the present invention is  
antisense and therefore has utility for use on cDNA arrays and oligonucleotide  
arrays (spotted oligos or solid phase synthesised oligos such as Affymetrix).  
Commercial or "home-made" arrays are either cDNA or oligo based (typically sense  
30 oligos are arrayed) and therefore production of antisense cRNA as we describe  
herein has utility in either setting. If sense RNA was generated then its use would be  
limited to cDNA arrays and not the majority of most current oligonucleotide arrays.

The present invention also overcomes the obstacle of limited tissue samples.

In a first aspect, the present invention relates to a cDNA-RNA hybrid comprising a first strand cDNA synthesis substantially hybridised to RNA wherein the cDNA  
5 comprises an amplifier sequence and an RNA annealing region operably linked to an RNA polymerase promoter, and wherein at least one non-templated nucleotide at the 3' end of the first strand cDNA is hybridised to a template switching oligonucleotide.

- 10 In a second aspect, the present invention relates to a method for amplifying RNA in a sample comprising the steps of: (a) providing a cDNA synthesis oligonucleotide comprising an amplifier sequence and an RNA annealing region operably linked to an RNA polymerase promoter; (b) annealing the RNA annealing region of the cDNA synthesis oligonucleotide to RNA under suitable conditions to produce a  
15 cDNA-RNA complex; (c) incubating said cDNA-RNA complex under conditions which permit template-dependent extension of the cDNA synthesis oligonucleotide to generate a cDNA-RNA hybrid; (d) contacting said cDNA-mRNA hybrid with a template switching oligonucleotide under conditions which permit template dependent extension of said cDNA, such that the 3' end of the cDNA comprises a  
20 sequence complementary to said template switching oligonucleotide; (e) providing an amplification primer under conditions to generate double stranded amplification products corresponding substantially to the first strand cDNA synthesis, such that the cDNA amplification products comprise a double stranded RNA polymerase promoter; and (f) incubating said cDNA amplification products comprising said  
25 double stranded RNA polymerase promoter under conditions that permit *in vitro* transcription to generate amplified RNA.

- In a third aspect, the present invention relates to a method for preparing an expression library of a cell or a cell population comprising the steps of: (a) providing  
30 a cDNA synthesis oligonucleotide comprising an amplifier sequence and an RNA annealing region operably linked to an RNA polymerase promoter; (b) contacting said cDNA synthesis oligonucleotide with a population of mRNAs from said cell or cell population under conditions to allow hybridisation of said cDNA synthesis

oligonucleotide to mRNA to produce a cDNA-mRNA complex; (c) incubating said cDNA-mRNA complex under conditions which permit template-dependent extension of said cDNA synthesis oligonucleotide to generate a cDNA-mRNA hybrid; (d) contacting said cDNA-mRNA hybrid with a template switching  
5 oligonucleotide under conditions which permit template dependent extension of said cDNA, such that the 3' end of the cDNA of the cDNA-mRNA hybrid comprises a sequence complementary to said template switching oligonucleotide; (e) contacting an amplification primer with said cDNA-mRNA hybrid under conditions that generate double stranded amplification products corresponding to the first strand  
10 cDNA synthesis, such that the double stranded cDNA amplification products comprise a double stranded RNA polymerase promoter; and (f) incubating said double stranded cDNA amplification products comprising said double stranded RNA polymerase promoter under conditions that permit *in vitro* transcription to generate amplified RNA.

15

In a fourth aspect, the present invention relates to a method of preparing a cDNA library from a collection of mRNA molecules comprising the steps of: (a) providing a cDNA synthesis oligonucleotide comprising an amplifier sequence and an RNA annealing region operably linked to an RNA polymerase promoter; (b) contacting  
20 said cDNA synthesis oligonucleotide with the collection of mRNAs under conditions to allow annealing of said cDNA synthesis oligonucleotide to mRNA  
produce a cDNA-mRNA complex; (c) incubating said cDNA-mRNA complex under conditions which permit template-dependent extension of said cDNA synthesis oligonucleotide to generate a cDNA-mRNA hybrid; (d) contacting said cDNA-  
25 mRNA hybrid with a template switching oligonucleotide under conditions which permit template dependent extension of said cDNA of said hybrid, such that the 3' end of the cDNA of the cDNA-mRNA hybrid comprises a sequence complementary to said template switching oligonucleotide; (e) contacting a PCR primer with said cDNA-mRNA hybrid under conditions that generate double stranded amplification  
30 products corresponding to the first strand cDNA synthesis, such that the double stranded cDNA amplification products comprise a double stranded RNA polymerase promoter; (f) incubating said double stranded cDNA amplification products comprising said double stranded RNA polymerase promoter under conditions that

permit *in vitro* transcription to generate amplified RNA; and (g) preparing a cDNA library from the amplified RNA.

In a fifth aspect, the present invention relates to a method for performing subtractive  
5 hybridisation comprising the steps of: (a) providing a cDNA synthesis oligonucleotide comprising an amplifier sequence and an RNA annealing region operably linked to an RNA polymerase promoter; (b) contacting the cDNA synthesis oligonucleotide with a collection of mRNAs under conditions to allow annealing of said cDNA synthesis oligonucleotide to mRNA in said RNA sample to produce a  
10 cDNA-mRNA complex; (c) incubating said cDNA-mRNA hybrid with enzyme, dNTPs and buffer under conditions which permit template-dependent extension of said cDNA synthesis oligonucleotide to generate a cDNA-mRNA hybrid; (d) contacting said cDNA-mRNA hybrid with a template switching oligonucleotide under conditions which permit template dependent extension of said cDNA of said  
15 hybrid, such that the 3' end of the cDNA of the cDNA-mRNA hybrid comprises a sequence complementary to said template switching oligonucleotide; (e) contacting an amplification primer with said cDNA-mRNA hybrid under conditions to generate double stranded amplification products corresponding to the first strand cDNA synthesis, such that the double stranded cDNA amplification products comprise a  
20 double stranded RNA polymerase promoter; (f) incubating said double stranded cDNA amplification products comprising said double stranded RNA polymerase promoter under conditions that permit *in vitro* transcription to generate amplified RNA; (g) contacting said amplified RNA with a single stranded nucleic acid population in the opposite sense to said amplified RNA; (h) providing for the  
25 hybridisation of the sequences present in the amplified RNA and the single stranded nucleic acid population; and (i) isolating the nucleic acid population that remains single stranded.

In a sixth aspect, the present invention relates to a method for detecting the  
30 expression of a gene of interest comprising the steps of: (a) providing a cDNA synthesis oligonucleotide comprising an amplifier sequence and an RNA annealing region operably linked to an RNA polymerase promoter, wherein the RNA annealing region comprises a sequence that is substantially homologous to the



mRNA expressed by the gene of interest; (b) contacting said cDNA synthesis oligonucleotide with a population of mRNAs in a cell or cell population under conditions to allow annealing of said cDNA synthesis oligonucleotide to mRNA to produce a cDNA-mRNA complex; (c) incubating said cDNA-mRNA hybrid under  
5 conditions which permit template-dependent extension of said cDNA synthesis oligonucleotide to generate a cDNA-mRNA hybrid; (d) contacting said cDNA-mRNA hybrid with a template switching oligonucleotide under conditions which permit template dependent extension of said cDNA of said hybrid, such that the 3' end of the cDNA of the cDNA-mRNA hybrid comprises a sequence complementary  
10 to said template switching oligonucleotide; (e) contacting an amplification primer with said cDNA-mRNA hybrid under conditions to generate double stranded amplification products corresponding to the first stand cDNA synthesis, such that the double stranded cDNA amplification products comprise a double stranded RNA polymerase promoter; (f) incubating said double stranded cDNA amplification  
15 products comprising said double stranded RNA polymerase promoter under conditions that permit *in vitro* transcription to generate amplified RNA; and (g) determining the presence or absence of amplified RNA, which amplified RNA is complementary to mRNA corresponding to the gene of interest.

20 In a seventh aspect, the present invention relates to amplified RNA obtainable by the method according to the second aspect of the present invention.

---

Advantageously, the amplified RNA could be used in a diagnostic, prognostic or predictive test starting with small limiting amounts of biological or clinical samples,  
25 for example but not limited to, biopsies, fine needle aspirates, tissue sections, bronchioalveolar lavage, macrodissected or microdissected tissues.

In an eighth aspect, the present invention relates to an expression library obtainable by the method according to the third aspect of the present invention..

30

In an ninth aspect, the present invention relates to a cDNA library obtainable by the method according to the fourth aspect of the present invention..

In a tenth aspect, the present invention relates to the use of a cDNA-RNA hybrid according to the first aspect of the present invention in the amplification of RNA.

In an eleventh aspect, the present invention relates to the use of a cDNA-RNA hybrid according to the first aspect of the present invention in the preparation of a cDNA library.

In an twelfth aspect, the present invention relates to the use of a cDNA-mRNA hybrid according to the first aspect of the present invention in subtractive hybridisation.

In an thirteenth aspect, the present invention relates to the use of a cDNA-mRNA hybrid according to the first aspect of the present invention for measuring gene expression.

15

In an fourteenth aspect, the present invention relates to a kit for the amplification of RNA in a sample comprising: (a) a cDNA synthesis oligonucleotide comprising an amplifier sequence and an RNA annealing region operably linked to an RNA polymerase promoter; (b) a template switching oligonucleotide that has substantially the same sequence as the amplifier sequence; and (c) an amplification primer that has substantially the same sequence as the template switching oligonucleotide.

Other aspects of the present invention are presented in the accompanying claims and in the following description and discussion. These aspects are presented under separate section headings. However, it is to be understood that the teachings under each section heading are not necessarily limited to that particular section heading.

#### PREFERRED EMBODIMENTS

Preferably, the RNA of the cDNA-RNA hybrid is mRNA.

30

Preferably, the RNA polymerase promoter is a bacteriophage promoter. More preferably, the bacteriophage promoter is selected from the group consisting of T7, T3 and SP6.

Preferably, the RNA annealing region comprises poly (dT). More preferably, the oligo(T) region is from about 10 to about 30 T residues in length.

- 5 Preferably, the 3' end of the RNA annealing region comprises a VN clamp (VN-3'), wherein V is A, G or C and N is A, G, C or T.

Preferably, at least one non-templated nucleotide at the 3' end of the first strand cDNA synthesis is deoxycytidine.

10

Preferably, at least three non-templated nucleotide at the 3' end of the first strand cDNA synthesis are hybridised to a template switching oligonucleotide.

- Preferably, at least three of the non-templated nucleotides at the 3' end of the first  
15 strand cDNA synthesis are deoxycytidine nucleotides.

Preferably, the template switching oligonucleotide has at least three guanine residues at its 3' end.

- 20 Preferably, the amplifier sequence, amplification primer and the template switching oligonucleotide contain the same sequence.
- 

Preferably, the 3' end of the first strand cDNA synthesis is extended such that it is substantially complementary to the template switching oligonucleotide.

25

Preferably, the first strand cDNA synthesis is synthesised by a reverse transcriptase.

- Preferably, the reverse transcriptase lacks RNaseH activity but retains wild-type polymerase activity. More preferably, the reverse transcriptase is a Moloney Murine  
30 Leukemia virus (MMLV) reverse transcriptase or a mutant thereof. Most preferably, the reverse transcriptase is PowerScript<sup>TM</sup> Reverse Transcriptase (BD Biosciences Clontech).

Preferably, the cDNA-RNA hybrid is incubated with a reverse transcriptase that adds at least one deoxycytidine residue to the 3' end of the first strand cDNA synthesis.

- 5 Preferably, the reaction comprises 1 mM dNTPs.

Preferably, the double stranded amplification products are obtained by PCR.

- 10 Preferably, the cDNA synthesis oligonucleotide and the PCR primer have the same concentration.

**Preferably, the cDNA synthesis oligonucleotide and the PCR primer have a concentration of about 0.5  $\mu$ M.**

- 15 Preferably, PCR amplification is performed using the Advantage® 2 Polymerase mix (BD Biosciences Clontech).

- Preferably, the optimum number of cycles to generate the double stranded amplification products is determined by a method comprising the steps of: (a) providing a plurality of samples with a known amount of RNA; (b) performing amplification for a defined number of cycles on the plurality of samples; (c) purifying the double stranded amplification products; (d) providing for the *in vitro* transcription of the purified amplification products; and (e) determining the number of amplification cycles that results in the minimum amount of amplified RNA that is required.
- 20
- 25

Preferably, the RNA sample is a clinical sample selected from the group consisting of a biopsy, a microdissected tissue, a fine needle aspirate, a flow-sorted cell, a laser captured microdissected cell or a single cell.

30

Preferably, gene expression is measured using a microarray.

Preferably, the kit according to the fourteenth aspect of the present invention further comprises in a separate container a reverse transcriptase.

Preferably, the kit further comprises in a separate container an RNA polymerase  
5 specific to the RNA polymerase promoter of the cDNA synthesis oligonucleotide.

Preferably, the kit further comprises an amplification buffer and one or more  
amplification enzymes. More preferably, the amplification buffer and the  
amplification enzyme(s) are PCR amplification buffer and PCR amplification  
10 enzyme(s).

Preferably, the kit further comprises a control nucleic acid.

#### ADVANTAGES

15 The present invention has a number of advantages. These advantages will be  
apparent in the following description.

By way of example, the present invention is advantageous since it provides a  
commercially useful method.

20

By way of further example, the present invention is advantageous since the method  
of the present invention is technically simpler and faster than alternative  
amplification methods, but with equivalent or improved performance over such  
methods.

25

By way of further example, the present invention is advantageous since the present  
invention provides a method for the reproducible and robust amplification of small  
amounts of total RNA (typically 5ng-50ng or less), or the approximate equivalent of  
500-5000 cells, with the possibility of further scope to use even lower amounts.

30

By way of further example, the present invention is advantageous since it provides a  
novel method for the amplification of limited amounts of RNA while maintaining  
the relative representation of mRNAs.

### BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows a representation of the amplification method according to the present invention.

5.

#### Step 1

Incubating a sample of poly(A)+RNA or total RNA in the presence of a cDNA synthesis oligonucleotide which can anneal to RNA.

- 10 This oligonucleotide has at the 5' end an amplification primer – such as a PCR primer - followed by a T7 promoter sequence and an RNA annealing region. The amplification primer generates the 3' anchor on the cDNA for subsequent amplification and the T7 promoter sequence allows the generation of amplified RNA targets by *in vitro* transcription. An enzyme possessing reverse transcriptase activity
- 15 is included under suitable conditions to generate an RNA-cDNA hybrid and a template switching oligonucleotide is also included which can provide CAP-dependent extension of full-length cDNA by reverse transcriptase using the template switching oligonucleotide as a template, and thereby adding sequence complementary to the template switching oligonucleotide to the 3'-end of full-length
- 20 cDNA.

#### Step 2

- Incubating anchored cDNA:RNA hybrid (*ie* the population of full-length cDNAs) generated at step 1, with a single amplification primer corresponding substantially or
- 25 completely to the sequence of the template switching oligonucleotide.

- Conditions suitable to generate amplification products are used, the amplification products corresponding to the population of cDNAs present. Advantageously, the amplification conditions are pre-determined to result in sufficient amounts of
- 30 amplified product for downstream applications but with the minimal number of amplification cycles to minimise any amplification bias. Amplification products are then purified by standard procedures.

### Step 3

The purified amplification products obtained undergo transcription-based amplification using T7 polymerase to generate amplified RNA (aRNA), also known as complementary RNA (cRNA), for downstream applications. The T7 promoter region that is incorporated into the cDNA synthesis oligonucleotide is capable of inducing transcription by T7 polymerase.

Figure 2 shows a comparison of cRNA yields.

10 Figure 3 illustrates quality control metrics across arrays. RawQ, BG log and Scaling factor values are shown for each GeneChip hybridisation.

Figure 4. Top: 3' to 5' ratios for the beta-actin (x00351) probe sets. Middle: 3' to 5' ratios for the GAPDH (m33197) probe sets. Bottom: The number of probe sets  
15 called Present as determined by the Affymetrix MAS 5.0 algorithm.

Figure 5 shows the detection of 5', middle, and 3' ends of polyA+ spikes. Top: Lys transcript spiked in at 1pM. Middle: Phe transcript spiked in at 5pM. Bottom: Thr transcript spiked in at 20pM. Each graph shows the signals for the 5'end , middle,  
20 and 3' end probe sets for the polyA+ spikes.

---

Figure 6 represents a clustering dendrogram using Pearson correlation.

Figure 7 illustrates scatter plots (log scale) for ~22,000 genes.

25

Figure 8 shows Spotfire scatter plots showing genes changing more than 2 fold ( $> |\log_{10} 0.3|$ ) between samples.

Figure 9 represents scatter plots comparing log ratios to those of Set A ("9µg 384  
30 non amp rep1 versus 9µg 842 non amp rep1"). Background noise has been removed from plots i.e. where a signal of <100 was reported for a particular gene across all chip hybridisations. Pearson correlation values are given for each comparison.

Figure 10 shows Cluster histograms. Upper histogram shows all genes in all clusters [Red = genes changing  $<2$  fold, Blue = genes changing  $>2$  fold]. Lower histogram shows only the genes changing  $>2$  fold (y axis enlarged). Numbers on the columns indicate how many genes are in each of the first 20 clusters.

5

Figure 11 shows example clusters [Red = genes changing  $<2$  fold, Blue = genes changing  $>2$  fold].

Figure 12 shows 70 k-means clusters [Red = genes changing  $<2$  fold, Blue = genes  
10 changing  $>2$  fold].

Figure 13 shows 70 k-means clusters [Red = genes changing  $<2$  fold].

Figure 14 shows 70 k-means clusters [Blue = genes changing  $>2$  fold].

15

## DETAILED DESCRIPTION OF THE INVENTION

### OLIGONUCLEOTIDE

The oligonucleotides according to the present invention may be DNA, RNA, chimeric mixtures or derivatives or modified versions thereof that are modified at  
20 the base moiety, sugar moiety or backbone and may include other appending groups or labels, so long as they are still capable of functioning in the desired reaction.

By way of example, the oligonucleotide may be a cDNA synthesis oligonucleotide comprising DNA.

25

By way of further example, the oligonucleotide may be a template switching oligonucleotide comprising DNA.

In a highly preferred embodiment, the template switching oligonucleotide is the  
30 template switching oligonucleotide described in US 5,962,271 and 5,962,272.

By way of further example, the oligonucleotide may be an amplification primer – such as a PCR primer - comprising DNA.



The oligonucleotides according to the present invention may be modified so long as they are still capable of functioning in the desired reaction.

- 5 The oligonucleotides may be modified at the base moiety, sugar moiety, or phosphate backbone, and may include other appending groups or labels.

The oligonucleotides may comprise at least one modified phosphate backbone — such as phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a  
10 phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or an analogue thereof.

The oligonucleotides may be derived by cleavage of a larger nucleic acid fragment using non-specific nucleic acid cleaving chemicals or enzymes or site-specific  
15 restriction endonucleases; or by synthesis by standard methods known in the art, e.g. by use of a commercially available automated DNA synthesiser and standard phosphoramidite chemistry.

Once the desired oligonucleotide is synthesised, it is cleaved from a solid support on  
20 which it was synthesised and treated, by methods known in the art, to remove any protecting groups present. The oligonucleotide may then be purified by any method known in the art, including extraction and gel purification. The concentration and purity of the oligonucleotide may be determined by, for example, examining the oligonucleotide on an acrylamide gel, by HPLC, or by measuring the optical density  
25 at 260 nm in a spectrophotometer.

In a preferred embodiment of the present invention, the oligonucleotide is a cDNA synthesis oligonucleotide comprising the sequence set forth in SEQ ID No 1:

30 5'AAGCAGTGGTATCAACGCAGAGTGGCCAGTGAATTGTAATACGACTCA  
CTATAGGGAGGCGG(T)<sub>30</sub>VN-3'

wherein V is A, G, or C and N is any base.

In another preferred embodiment, the oligonucleotide is a cDNA synthesis oligonucleotide comprising the sequence set forth in SEQ ID No 4:

5 5'AAGCAGTGGTATCAACGCAGAGTAATACGACTCACTATAGGGAGA(T)<sub>24</sub>  
VN-3'

wherein V is A, G , or C and N is any base.

10 In yet another preferred embodiment of the present invention, the oligonucleotide is a template switching oligonucleotide comprising the sequence set forth in SEQ ID No. 2:

5'-AAGCAGTGGTATCAACGCAGAGTACGCGGG-3'

15

In still another preferred embodiment, the oligonucleotide is an amplification primer comprising the sequence set forth in SEQ ID No. 3:

5'-AAGCAGTGGTATCAACGCAGAGT-3'

20

The oligonucleotides corresponding to SEQ ID Nos 2 and 3 have been described in US 5,962,271 and 5,962,272.

In the context of the present invention, the cDNA synthesis oligonucleotide  
25 comprises an amplifier sequence and an RNA annealing region operably linked to an RNA polymerase promoter.

#### AMPLIFIER SEQUENCE

The amplifier sequence in the context of the present invention relates to a portion of  
30 the cDNA synthesis oligonucleotide that contains the same or substantially the same sequence as the template switching oligonucleotide and the amplification primer, as described herein.

The amplification primer is able to hybridise to the complementary sequence of the amplifier sequence, such that the second strand cDNA synthesis may be amplified by, for example, PCR.

- 5 Preferably, the amplifier sequence is located at the 5' end of the cDNA synthesis oligonucleotide and generally, will not be translated into RNA.

A person skilled in the art will appreciate that any sequence may be used for the amplifier sequence as long as the amplification primer is able to hybridise or  
10 substantially hybridise to the complementary sequence of the amplifier sequence.

The substantially identical template switching oligonucleotide and the amplifier sequence at both ends of the cDNA serve as universal priming sites for end-to-end amplification of the cDNA population.

15

In a preferred embodiment, the amplifier sequence, the amplification primer and the template switching oligonucleotide contain the substantially the same sequence – such as regions with the same sequence.

- 20 In another preferred embodiment, the amplifier sequence comprises the sequence set forth in SEQ ID No. 3.
- 

#### RNA ANNEALING REGION

As used herein, the term “RNA annealing region” refers to a portion of the cDNA  
25 synthesis oligonucleotide that is able to anneal to RNA.

For many applications, it is desirable to preferentially enrich for one type of RNA with respect to other cellular RNAs, such as messenger RNA (mRNA), transfer RNA (tRNA) and ribosomal RNA (rRNA). Advantageously, most mRNAs contain  
30 a poly(A) tail at their 3' end which allows them to be enriched by affinity chromatography, for example, using oligo(dT) or poly(U) coupled to a solid support - such as cellulose or Sephadex (Ausubel et al., eds., 1994, Current Protocols in Molecular Biology, vol. 2, Current Protocols Publishing, New York).

Accordingly, in a preferred embodiment of the present invention, the RNA annealing regions comprises poly(dT). Preferably, the poly(dT) is a polythymidylate region comprising about 10 to 30, preferably about 15 to 25, most  
5 preferably about 20 T residues, which bind with the poly(A) tail present on the 3' terminus of each mRNA.

If more sequence information is available for a given RNA, then the RNA annealing region may be designed more specifically to hybridise with a more specific  
10 population of RNA. Moreover, the RNA annealing region may comprise a collection of RNA annealing regions.

Also, if there is ambiguity in the sequence information, a number of RNA annealing regions may be present. Thus, by way of example, when several possible nucleic  
15 acid sequences that encode a protein could be correct based on the protein sequence, a collection of RNA annealing regions containing sequences representing most or all of the possible codon variations may be prepared.

If the sequence information for the desired RNA is known, the RNA annealing  
20 region need not reflect the exact sequence of the RNA, and can be "degenerate". Non-complementary bases or longer sequences can be interspersed into the RNA annealing region, provided that the RNA annealing region has sufficient complementarity with the sequence of the strand to be amplified to permit hybridisation.

25

Typically, the RNA annealing region is located at the 3' end of the cDNA synthesis oligonucleotide and is operably linked to the RNA polymerase promoter.

The term "operably linked" refers to a juxtaposition wherein the RNA annealing  
30 region and the RNA polymerase promoter are in a relationship permitting them to function in their intended manner. Thus, in the context of the present invention, the RNA annealing region and the RNA polymerase promoter are in a relationship that

permits the RNA annealing region to be expressed from the RNA polymerase promoter.

Advantageously, the 3' end of the RNA annealing region may comprise one or more  
5 nucleotides that assist in the priming of mRNA. Preferably, the nucleotides comprise a VN clamp, wherein V is A, G or C and N is A, G, C or T.

#### RNA POLYMERASE PROMOTER

Promoter sequences are regions where RNA polymerase binds tightly to DNA and  
10 contains the start site and signal for RNA synthesis to begin.

The RNA polymerase promoter will usually comprise between about 15 and 250 nucleotides, preferably between about 15 and 60 nucleotides, most preferably between about 15 and 40 nucleotides, from a naturally occurring RNA polymerase  
15 promoter or a consensus promoter region (Alberts *et al.*, in Molecular Biology of the Cell, 2d Ed., Garland, N.Y. (1989)). Native strong promoters typically contain two highly conserved DNA sequences, each about six nucleotides long, which are located upstream from the start site and separated from each other by about 17 nucleotides of unrecognised DNA.

20

---

The RNA polymerase that is used for transcription must be capable of binding to the particular RNA polymerase promoter region that is present in the cDNA synthesis oligonucleotide according to the present invention. In practice, any combination of RNA polymerase and RNA polymerase promoter may be used as long as the  
25 polymerase has sufficient specificity for that promoter to initiate *in vitro* transcription.

The promoter may be a prokaryotic or a eukaryotic promoter. Preferably, the promoter is a prokaryotic promoter. More preferably, the prokaryotic promoter is a  
30 phage or virus promoter. Most preferably, the RNA polymerase promoter is a promoter derived from a bacteriophage, for example, T3, T7 or SP6 polymerase (Chamberlin and Ryan, in The Enzymes, ed. P. Boyer (Academic Press, New York) pp. 87-108 (1982)).

A typical sequence of the T3 RNA polymerase promoter is:

5' GCATTAACCCTCACTAAC 3' (SEQ ID No. 5)

5

A number of variant T3 promoter sequences are also known, especially those in which the first three bases of the non-template strand (shown above) are 5' TTA 3', rather than AAA. See for example, US 5,037,745.

10 A typical sequence of the T7 RNA polymerase promoter is:

5' TAATACGACTCACTATA 3' (SEQ ID No. 6)

A number of variant forms of T7 RNA polymerase are also known in the art. By way of example only, further variants of the T7 RNA polymerase promoter are:

15

5' AATACGACTCACTATAGGGAGA 3' (SEQ ID No. 7)

and

20

5' GGCCAGTGAATTGTAATACGACTCACTATAGGGAGGCGG 3' (SEQ ID No. 8)

A typical sequence of the SP6 RNA polymerase promoter is:

25

5' ATTTAGGTGACACTATA 3' (SEQ ID No. 9)

The RNA polymerase promoter may be a hybrid promoter.

30 The promoter may additionally include features to ensure or to increase the level of expression.

The most preferred promoter is a T7 RNA polymerase promoter. The very high degree of specificity shown by T7 RNA polymerase for its promoter site (Chamberlin et al., in *The Enzymes*, ed. P. Boyer (Academic Press, New York) pp. 87-108 (1982)) has made this enzyme a widely used reagent in a variety of recombinant DNA techniques. The natural T7 promoters share a highly conserved sequence covering about bp -17 to about +6 relative to the start of the RNA chain (Dunn and Studier, *J. Mol. Biol.* 166: 477-535 (1983) and *J. Mol. Biol.* 175: 111-112 (1984)). The lack of efficient termination signals for T7 polymerase also enable it to make transcripts from almost any DNA (see, Rosenberg et al., *Gene* 56: 125-135 (1987)).

RNA polymerases are widely available from a number of commercial sources - such as Promega Corporation, Ambion Inc, Enzo Diagnostics Inc., Epicentre Technologies.

15

The RNA polymerase promoter may be single stranded or double stranded. Advantageously, following the PCR amplification step of the method described herein, the promoter becomes double stranded.

20 In a highly preferred embodiment, the orientation of the RNA polymerase promoter is such that antisense aRNA is expressed. Advantageously, antisense aRNA may be used in cDNA arrays and oligonucleotide arrays - such as spotted oligonucleotides or solid phase synthesised oligonucleotides eg. Affymetrix. Commercial or "home-made" arrays are either cDNA or oligonucleotide based (typically sense oligonucleotides are arrayed) and therefore  
25 production of antisense cRNA as we describe herein has utility in either setting.

### TEMPLATE SWITCHING

Template switching refers to the process of template-dependent synthesis of the complementary strand by an enzyme - such as reverse transcriptase - using two templates in consecutive order and which are not covalently linked to each other by phosphodiester bonds.

The process of template switching is described in Chenchik, et al (1998), Clark, (1988) and Hu & Temin, (1990), US 5,962,271 and US 5,962,272.

Template switching in the context of the present invention is achieved by utilising  
5 two of the intrinsic properties of reverse transcriptase namely the ability to add non-templated nucleotides to the 3' end of the first-strand cDNA, and the ability to switch templates.

Preferably, the template switching oligonucleotide comprises more than one residue  
10 – at its 3' end that base pairs with the complementary residues that are added at the 3' end of the cDNA. More preferably, the template switching oligonucleotide comprises at least two residues at its 3' end that base pairs with the complementary residues that are added at the 3' end of the cDNA. Most preferably, the template switching oligonucleotide comprises at least three residues at its 3' end that base  
15 pairs with the complementary residues that are added at the 3' end of the cDNA.

Preferably, at least one of the residues at the 3' end of the template switching oligonucleotide comprise deoxyguanidine nucleotides. More preferably, at least two of the residues at the 3' end of the template switching oligonucleotide comprise  
20 deoxyguanidine nucleotides. More preferably, at least three of the residues at the 3' end of the template switching oligonucleotide comprise deoxyguanidine nucleotides. Most preferably, three of the residues at the 3' end of the template switching oligonucleotide comprise deoxyguanidine nucleotides.

25 Reverse transcriptase replicates to the 5' end of the mRNA then switches templates and continues to replicate to the end of the template switching oligonucleotide. The resulting first-strand cDNA synthesis contains the complete 5' ends of the mRNA's as well as sequences complementary to the template switching oligonucleotide.

30 The substantially identical template switching oligonucleotide and the amplifier sequence at both ends of the cDNA serve as universal priming sites for end-to-end cDNA amplification of the cDNA population.



A person skilled in the art will appreciate that any sequence may be used for the template switching oligonucleotide as long as it is identical or substantially identical to the amplification primer. Accordingly, in a preferred embodiment of the present invention the template switching oligonucleotide has substantially the same  
5 sequence as the amplifier sequence.

The 3' end of the first strand cDNA synthesis is extended such that it is complementary or substantially complementary to the template switching oligonucleotide. Advantageously, an amplification primer is used that is able to  
10 hybridise to the sequence that is complementary to the template switching oligonucleotide. A DNA polymerase is then able to extend from the 3' end of the hybridised or substantially hybridised amplification primer, thereby resulting in a second strand cDNA synthesis.

#### 15 cDNA-RNA HYBRID

In the context of the present invention, a cDNA-RNA hybrid refers to a hybrid that is formed between RNA and a first-strand cDNA synthesis in which the cDNA is extended such that the first-strand cDNA synthesis is complementary or substantially complementary to the RNA.

20

Typically, at least one non-templated nucleotide at the 3' end of the first strand cDNA is hybridised to a template switching oligonucleotide in the cDNA-RNA hybrid.

---

25 Preferably, at least one non-templated nucleotide at the 3' end of the first strand cDNA synthesis is deoxycytidine. More preferably, at least two non-templated nucleotides at the 3' end of the first strand cDNA synthesis are hybridised to a template switching oligonucleotide. More preferably, at least three non-templated nucleotides at the 3' end of the first strand cDNA synthesis are hybridised to a  
30 template switching oligonucleotide.

Preferably, at least one of the non-templated nucleotides at the 3' end of the first strand cDNA synthesis are deoxycytidine nucleotides. More preferably, at least two

of the non-templated nucleotides at the 3' end of the first strand cDNA synthesis are deoxycytidine nucleotides. Most preferably, at least three of the non-templated nucleotides at the 3' end of the first strand cDNA synthesis are deoxycytidine nucleotides.

5

Preferably, the hybrid is a cDNA-mRNA hybrid.

Typically, the first strand cDNA synthesis is catalysed by a reverse transcriptase using the RNA of the cDNA-mRNA as a template.

10

#### cDNA-RNA COMPLEX

A cDNA-RNA complex refers to a complex that is formed between RNA and a cDNA synthesis oligonucleotide in which the RNA annealing region of the cDNA synthesis oligonucleotide is hybridised or substantially hybridised to a

15 complementary or substantially complementary RNA.

The RNA template-dependent extension of the cDNA synthesis oligonucleotide results in extension of the cDNA synthesis oligonucleotide such that the first-strand cDNA synthesis is complementary or substantially complementary to RNA, thus

20 forming a cDNA-mRNA hybrid.

Preferably, the complex is a cDNA-mRNA complex.

#### SAMPLE

25 A sample in the context of the present invention may be any entity that comprises RNA.

Any RNA, in purified or non-purified form, may be utilised in the method of the present invention, provided that it contains or is suspected to contain the RNA that is  
30 of interest. The desired RNA may be a minor or a major fraction of a complex mixture. Accordingly, the present invention is useful not only for producing large amounts of one specific nucleic acid sequence, but also for amplifying simultaneously one or more different specific nucleic acid sequences.

The RNA – such as cloned RNA or total RNA – may be obtained from any prokaryotic or eukaryotic source, for example, bacteria, yeast, viruses, organelles, and higher organisms such as plants or animals. RNA may be extracted from blood,  
5 tissue material or cells by a variety of techniques such as those described in Maniatis *et al.*, *supra*.

Accordingly, the sample may be or may be derived from biological material.

- 10 The sample may be a clinical sample - such as a biopsy, microdissected tissue or laser-captured cells. Preferably, the sample is a small sample, for example, a small biopsy, a fine needle aspirate, a macrodissected tissue, a flow-sorted cell, a laser captured microdissected cell or a small number of cells – such as a single cell.
- 15 Advantageously, the present invention provides a method for the reproducible and robust amplification of small amounts of total RNA. Preferably, the present invention is able to amplify 5-50 ng of total RNA, more preferably, the present invention is able to amplify 5-25ng total RNA, most preferably, the present invention is able to amplify 5 ng or less total RNA with the possibility of further  
20 scope to use even lower amounts.

---

5-50ng total RNA equates to the approximate equivalent of 500-5000 cells.

Total cellular RNA, cytoplasmic RNA, or poly(A)+ RNA may be used. Methods for  
25 preparing total and poly(A)+ RNA are well known and are described generally in Sambrook et al. (1989, Molecular Cloning--A Laboratory Manual (2nd Ed.), Vols. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.) and Ausubel et al., eds. (1994, Current Protocols in Molecular Biology, vol. 2, Current Protocols Publishing, New York).

30

Preferably, total RNA is prepared by the techniques described in Chirgwin et al, (1987), Chomczynski & Sacchi (1987), Sambrook et al, (1989), or Farrell Jr. (1993), and a number of high quality commercial kits are also available. More preferably,

total RNA used is prepared using the guanidinium thiocyanate method of Chirgwin et al, (1987).

The integrity of total RNA may be checked using various methods that are known in the art. By way of example, the RNA may be analysed using RNA gel electrophoresis (eg formaldehyde/ agarose gel), or Agilent LabChip. For mammalian total RNA, two bands at approximately 4.5 and 1.9 kb should be visible; these bands represent 28S and 18S ribosomal RNA respectively, and the ratio of intensities of these bands should typically be 1.5–2.5:1.

RNA purification kits for microscale RNA preparation are available from a number of commercial suppliers (for example Absolutely RNA™ Nanoprep, Stratagene; PicoPure™, Arcturus; RNeasy®, Qiagen; RNAqueous™ Microkit, Ambion).

Generally, the RNA samples are immediately snap-frozen in liquid nitrogen and then stored at –80°C until RNA extraction.

Typically, the total RNAs are treated with RNase-free DNaseI, which may be obtained from various manufacturers – such as Ambion's DNA-free™ kit.

#### cDNA SYNTHESIS

In accordance with the present invention, the first and second strand cDNA synthesis may be performed in separate tubes. Advantageously, the first and the second strand synthesis are performed in the same tube which enhances the synthesis procedure, maximises recovery of cDNA and makes the method simpler and quicker to perform.

The cDNA synthesis oligonucleotide for first strand cDNA synthesis may be hybridised to RNA in a suitable buffer at a temperature between about 60°C and 90°C, preferably about 70°C for about 5 minutes, followed by cooling to about 4 °C, before the reverse transcriptase is added.

Following the hybridisation of the cDNA synthesis oligonucleotide to RNA, a first cDNA strand is synthesised. This first strand of cDNA is preferably produced

through the process of reverse transcription, wherein DNA is made from RNA, utilising reverse transcriptase following methods that are familiar to a person skilled in the art.

- 5 Advantageously, any reverse transcriptase may be used in the present invention as long as the enzyme adds deoxyribonucleotides to the 3' terminus following extension (Varmus, Science 240: 1427-1435 (1988)) and the enzyme lacks RNase H activity.

10 Preferably, the reverse transcriptase lacks RNaseH activity but retains wild-type polymerase activity such that longer cDNA's can be synthesised. More preferably, the reverse transcriptase is Moloney Murine Leukemia virus (MMLV) reverse transcriptase or a mutant thereof. Most preferably, the reverse transcriptase is PowerScript™ Reverse Transcriptase (BD Biosciences Clontech).

- 15 The amount of reverse transcriptase employed may vary as will be appreciated by a person skilled in the art. The reverse transcription is performed by incubation for, for example, approximately 1 hour with reverse transcriptase at an appropriate temperature, which must be in a temperature range in which the reverse transcriptase retains enzyme activity.

20

---

The reaction may be performed between 37°C and 55°C, preferably between 37°C and 42°C.

- Most preferably, the reaction is performed at optimal enzyme activity – such as at  
25 about 42 °C.

The reverse transcription reaction may be terminated by heating the reaction mixture to 95 °C for about 5 minutes to inactivate the enzyme, optionally, followed by chilling on ice.

30

The first strand cDNA synthesis step may be modified by including dNTP's – such as 1 mM dNTP's - in the initial step in the procedure where the RNA is annealed to the cDNA synthesis oligonucleotide, by, for example heating to 70°C for 2 min.

This inclusion of dNTPs has previously been shown to increase the efficiency in another application, namely RT-PCR reactions (Huang, *et al*, (2000)). Advantageously, this modification may increase the yield of cRNA, from defined small amounts of starting total RNA. Although the mechanism for this observation is not known, without wishing to be bound by any particular theory, it may be due to stabilisation of RNA-primer hybridisation, and/or may help stabilisation of the template switching mechanism.

Advantageously, this modification allows a reduced number of amplification (eg. PCR) cycles with limited starting material, and may therefore help minimise any distortions to the mRNA distribution.

Typically, a single cycle of reverse transcription is carried out. More than one cycle of reverse transcription may be performed (with denaturation in between cycles).

#### AMPLIFICATION

"Amplification" refers to a process for multiplying nucleic acid strands *in vitro*.

In a highly preferred embodiment, the amplification method of the present invention is used for multiplying DNA strands – such as cDNA - *in vitro*.

An exemplary technique is PCR, which exponentially amplifies nucleic acid molecules.

PCR is described in US 4,683,195 and US 4,683,202. PCR consists of repeated cycles of DNA polymerase generated primer extension reactions. The target DNA is heat denatured and two oligonucleotides, which bracket the target sequence on opposite strands of the DNA to be amplified, are hybridised. These oligonucleotides become primers for use with DNA polymerase. The DNA is copied by primer extension to make a second copy of both strands. By repeating the cycle of heat denaturation, primer hybridisation and extension, the target DNA can be amplified a million fold or more in about two to four hours. PCR is a molecular biology tool which must be used in conjunction with a detection technique to determine the

results of amplification. An advantage of PCR is that it increases sensitivity by amplifying the amount of target DNA by 1 million to 1 billion fold in approximately 4 hours.

- 5 PCR may be used in the methods of the present invention as follows. A DNA polymerase – such as *Taq* DNA polymerase – is added to the reaction in addition to a single PCR primer that comprises substantially the same sequence as the amplifier sequence of the cDNA synthesis oligonucleotide.
- 10 In a preferred embodiment, the polymerase that is used is Advantage® 2 Polymerase Mix (BD Biosciences Clontech), which allows efficient and accurate amplification of cDNA templates by long-distance PCR (Barnes, 1994). The Advantage® 2 Polymerase Mix contains TITANIUM™ *Taq* DNA Polymerase, a nuclease-deficient N-terminal deletion of *Taq* DNA Polymerase, and a minor amount of a proofreading
- 15 polymerase. Advantage® 2 Polymerase Mix also contains TaqStart™ Antibody (BD Biosciences Clontech) to provide automatic hot-start PCR (Kellogg et al., 1994) and reduce non-specific priming of template. This combination allows efficient amplification of full-length cDNAs with a significantly lower error rate than that of conventional PCR (Barnes, 1994).

20

---

The single PCR primer hybridises substantially to the 3' end of the first strand cDNA synthesis (after denaturation) which corresponds to the complementary sequence of the template switching oligonucleotide. The DNA polymerase extends from the 3' end of the PCR primer resulting in a complementary cDNA second strand synthesis.

- 25 In subsequent rounds of PCR, the single PCR primer is able to hybridise to the 3' end of the first strand of the cDNA molecule (and all the amplified copies of the first strand) and to the 3' end of the second strand of the cDNA molecule (and all the amplified copies of the second strand), resulting in amplification.
- 30 The primer is preferably a single stranded oligodeoxynucleotide. The primer must be sufficiently long to act as a template for the synthesis of extension products in the presence of the replicating enzyme. The exact lengths of the primers and the

quantities used will depend on many factors, including temperature, degree of homology and other conditions.

For example, when amplifying a specific sequence, the oligonucleotide primer typically contains between about 10 and 50 nucleotides, preferably 15-25 or more nucleotides, although it may contain fewer nucleotides, depending. For other applications, the oligonucleotide primer is typically, but not necessarily, shorter, e.g., 7-15 nucleotides. Such short primer molecules generally require cooler temperatures to form sufficiently stable hybrid complexes.

10

In a preferred embodiment of the present invention, the PCR primer and the cDNA synthesis oligonucleotide are provided at the same concentration in the reaction.

In another preferred embodiment, the cDNA synthesis oligonucleotide and the PCR primer have a concentration of about, for example, 0.5  $\mu$ M.

The oligonucleotide primers may be prepared using any suitable method, such as, for example, the well known phosphotriester and phosphodiester methods, or automated embodiments thereof. One method for synthesising oligonucleotides on a modified solid support is described in US 4,458,066. It is also possible to use a primer which has been isolated from a biological source (such as a restriction endonuclease digest).

In a preferred embodiment, the PCR primer comprises the sequence set forth in SEQ ID No. 3.

PCR amplification is performed using methods that are well known in the art. By way of example only, the thermal cycling parameters of the PCR reactions may comprise 60 sec at 95°C for hot start, followed by 3 step cycling for a predetermined numbers of cycles of denaturation for 15 sec at 95°C, annealing for 30 sec at 65°C, and extension for 6 min at 68°C. Reactions may then be held at 4°C in the thermal cyclers until purification.



Advantageously, an improved method for determining the optimal number of amplification cycles that are required from a given amount of starting material may be utilised. For any amplification method – such as PCR - one of the key factors is to perform the minimum number of cycles (for a given amount of starting material) 5 that will result in sufficient target for the intended downstream application. If too many cycles are performed, then it is likely that the representation of RNAs – such as mRNAs - could be biased as the amplification reactions are unlikely to be identical for each RNA template in the complex mixture, and the amplification reaction may also reach a plateau. If too few cycles are performed then insufficient 10 amplification product may be obtained for subsequent applications.

In the method described here, for a given amount of starting total RNA (eg 50ng or 5ng), the minimum numbers of amplification cycles that are required are determined empirically such that when the entire amplification products are then used for *in-* 15 *vitro* transcription (IVT) reactions to generate cRNA, sufficient cRNA for the intended downstream application is obtained. This can be done by starting with a given amount of total RNA (eg 5ng or 50ng) by setting up identical reactions and performing an amplification reaction for defined numbers of cycles (or by removing aliquots from an amplification reaction for analysis and performing additional cycles 20 on the remainder of the amplification reaction). The entire amplification products from each reaction (for example 50ng starting total RNA that has undergone PCR thermal cycling for 9, 10, 11, 12, 13 or 14 cycles) is purified and used for IVT. The number of cycles that gives the minimum amount of cRNA that is sufficient for the downstream application is then determined. This number of cycles can then be used 25 routinely for similar studies with other RNA's at the same starting concentrations.

Advantageously, the amplification step can also be enhanced by addition of dNTP's in the initial step in the procedure where the RNA is heated to 70°C for 2 minutes.

30 In a preferred embodiment, about 1 mM dNTPs are added to the RNA/primer mix when the samples are being denatured prior to reverse transcription.

This means that less amplification is required with limited amounts of starting material and therefore help minimise any distortions to the mRNA distributions.

The amplification products that are obtained will typically be purified. This may be  
5 achieved using various methods that are known in the art. By way of example, PCR products may be purified using QIAGEN Qiaquick columns as per manufacturer's instructions.

#### SUBSTANTIALLY

10 The term "substantially" when used in relation to annealing or hybridisation, means that an oligonucleotide – such as a primer - should be sufficiently complementary to hybridise or anneal to its respective nucleic acid.

The oligonucleotide sequence need not reflect the exact sequence of its respective  
15 nucleic acid, and can, in fact, be "degenerate". Non-complementary bases or other sequences may be interspersed into the oligonucleotide or the nucleic acid, provided that the oligonucleotide sequence has sufficient complementarity with the sequence to permit hybridisation. Thus, by way of example, the primers used for PCR amplification may be selected to be "substantially" complementary to the specific  
20 sequence to be amplified.

#### HYBRIDISATION

As used herein, the term "hybridisation" refers to the process by which a strand of nucleic acid joins with a complementary strand through base pairing as well as the  
25 process of amplification as carried out in, for example, polymerase chain reaction (PCR) technologies.

The present invention encompasses the use of nucleotide sequences that are capable of hybridising to nucleotide sequences.

30

#### TRANSCRIPTION

The PCR reaction step described above results in a double stranded T7 RNA polymerase promoter that is operably linked to a double stranded DNA sequence.

By utilising a double stranded T7 promoter, the DNA sequence that is operably linked to the promoter may be transcribed into RNA. Various methods for *in vitro* transcription are well known in the art and many commercial kits are readily  
5 available.

By way of example only, the ENZO ® BioArray™ HighYield™ RNA Transcript Labelling Kit, Affymetrix (900182) may be used. The necessary reagents for the *in vitro* transcription are combined with the PCR reactions and *in vitro* transcription is performed at an appropriate time and temperature – such as 37°C for 5hrs. The  
10 incubation time may be varied depending upon how many transcripts it is desired to generate.

Depending on the ultimate use of the RNA, the necessary ribonucleotide triphosphates will be included in the transcription reaction mixture. One or more of  
15 the ribonucleotides may be labelled, with for example, a radioactive label, biotin, or the like. A wide variety of labelling techniques are well known to those skilled in the art and may be used in accordance with standard procedures, as described in US 4,755,619, for example.

20 Once the RNA transcripts have been obtained, various well known procedures may be employed for their processing. The transcripts may be removed from the reaction mixture and purified using various methods known in the art – such as the RNeasy® Mini columns (QIAGEN) as per manufacturer's instructions. The aRNA may be used as template for cDNA synthesis and subjected to PCR to further expand desired  
25 sequences. The aRNA may be used unmodified for further cloning, expression, use as probe or driver nucleic acid in subtractive hybridisation and the like.

#### AMPLIFIED RNA

As used herein, the term amplified RNA (aRNA) is used interchangeably with the  
30 term complementary RNA (cRNA).

aRNA refers to the amplified antisense RNA that is obtained from *in vitro* transcription of the double-stranded cDNA template using an RNA polymerase.

LABEL

In accordance with the present invention, amplified RNA may be labelled during *in vitro* transcription to facilitate its detection/use in subsequent steps.

5

The amplified RNA may be directly labelled with any label that is known in the art, including, but not limited to, radioactive labels, fluorophores, chemiluminescent molecules, or enzymatic markers – such as those that produce a detectable signal when a particular chemical reaction is conducted - and the like.

10

Alternatively, ribonucleotides may be obtained which are labelled with, for example, biotinylated CTP and UTP, where these ribonucleotides will become incorporated in the amplified RNA. The biotin may then be used for binding to avidin, which is labelled with an appropriate label capable of providing for detection. Other  
15 modified ribonucleotides - such as cyanine 3 and cyanine 5 CTP and UTP, or aminoallyl UTP can be readily incorporated into amplified RNA. A wide variety of labelling techniques are well known to those skilled in the art.

Labelling of RNA may be accomplished by including one or more labelled NTPs in  
20 the *in vitro* transcription reaction mixture. NTPs may be directly labelled with a radioisotope, such as  $^{32}\text{P}$ ,  $^{35}\text{S}$ ,  $^3\text{H}$ . NTPs may be directly labelled with a fluorescent label - such as fluorescein isothiocyanate, lissamine, Cy3, Cy5, and rhodamine 110.

RNA may also be indirectly labelled by incorporating a nucleotide linked covalently  
25 to a hapten or to a molecule - such as biotin - to which a labelled avidin molecule may be bound, or digoxigenin, to which a labelled anti-digoxigenin antibody may be bound. RNA may be labelled with labelling moieties during chemical synthesis or the label may be attached after synthesis by methods known in the art.

30 Often it is desired to compare gene expression in two different populations of cells, perhaps derived from different tissues or perhaps exposed to different stimuli. Such comparisons are facilitated by labelling the RNAs from one population with a first fluorophore and the RNAs from the other population, with a second fluorophore,

where the two fluorophores have distinct emission spectra. Again, Cy3 and Cy5 are particularly preferred fluorophores for use in comparing gene expression between two different populations of cells.

## 5 NUCLEOTIDE SEQUENCE

As used herein, the term "nucleotide sequence" is synonymous with the term "polynucleotide".

Aspects of the present invention involve the use of nucleotide sequences, which may  
10 be available in databases.

The nucleotide sequence may be DNA or RNA of genomic or synthetic or recombinant origin. The nucleotide sequence may be double-stranded or single-stranded whether representing the sense or antisense strand or combinations thereof.

15

The nucleotide sequence may be prepared by use of recombinant DNA techniques (e.g. recombinant DNA).

The nucleotide sequence may be the same as the naturally occurring form, or may be  
20 derived therefrom.

---

## VARIANTS/HOMOLOGUES/DERIVATIVES

In the context of the present invention, reference to nucleic and amino acid sequences includes mutants, variants, homologues, derivatives or fragments thereof.

25 Moreover, reference to a particular polypeptide includes mutants, variants, homologues, derivatives or fragments thereof which have the activity of the naturally occurring polypeptide and includes those polypeptides that differ from naturally occurring forms by having amino acid deletions, substitutions, and additions.

30

Thus, the present invention encompasses the use of variants, homologues and derivatives of nucleotide and amino acid sequences. Here, the term "homologue"

means an entity having a certain homology with amino acid sequences or nucleotide sequences. Here, the term "homology" can be equated with "identity".

In the present context, an homologous sequence is taken to include an amino acid  
5 sequence which may be at least 75, 85 or 90% identical, preferably at least 95 or 98% identical to the subject sequence. Although homology can also be considered in terms of similarity (i.e. amino acid residues having similar chemical properties/functions), it is preferred to express homology in terms of sequence identity.

10

An homologous sequence is taken to include a nucleotide sequence which may be at least 75, 85 or 90% identical, preferably at least 95 or 98% identical to the subject sequence.

15 Homology comparisons can be conducted by eye, or more usually, with the aid of readily available sequence comparison programs. These commercially available computer programs can calculate % homology between two or more sequences.

% homology may be calculated over contiguous sequences, i.e. one sequence is  
20 aligned with the other sequence and each amino acid in one sequence is directly compared with the corresponding amino acid in the other sequence, one residue at a time. This is called an "ungapped" alignment. Typically, such ungapped alignments are performed only over a relatively short number of residues.

25 Although this is a very simple and consistent method, it fails to take into consideration that, for example, in an otherwise identical pair of sequences, one insertion or deletion will cause the following amino acid residues to be put out of alignment, thus potentially resulting in a large reduction in % homology when a global alignment is performed. Consequently, most sequence comparison methods  
30 are designed to produce optimal alignments that take into consideration possible insertions and deletions without penalising unduly the overall homology score. This is achieved by inserting "gaps" in the sequence alignment to try to maximise local homology.

However, these more complex methods assign "gap penalties" to each gap that occurs in the alignment so that, for the same number of identical amino acids, a sequence alignment with as few gaps as possible - reflecting higher relatedness  
5 between the two compared sequences - will achieve a higher score than one with many gaps. "Affine gap costs" are typically used that charge a relatively high cost for the existence of a gap and a smaller penalty for each subsequent residue in the gap. This is the most commonly used gap scoring system. High gap penalties will of course produce optimised alignments with fewer gaps. Most alignment programs  
10 allow the gap penalties to be modified. However, it is preferred to use the default values when using such software for sequence comparisons. For example when using the GCG Wisconsin Bestfit package the default gap penalty for amino acid sequences is -12 for a gap and -4 for each extension.

15 Calculation of maximum % homology therefore firstly requires the production of an optimal alignment, taking into consideration gap penalties. A suitable computer program for carrying out such an alignment is the GCG Wisconsin Bestfit package (University of Wisconsin, U.S.A.; Devereux *et al.*, 1984, *Nucleic Acids Research* 12:387). Examples of other software than can perform sequence comparisons  
20 include, but are not limited to, the BLAST package (see Ausubel *et al.*, 1999 *ibid* - Chapter 18), FASTA (Atschul *et al.*, 1990, *J. Mol. Biol.*, 403-410) and the GENEWORKS suite of comparison tools. Both BLAST and FASTA are available for offline and online searching (see Ausubel *et al.*, 1999 *ibid*, pages 7-58 to 7-60). However, for some applications, it is preferred to use the GCG Bestfit program. A  
25 new tool, called BLAST 2 Sequences is also available for comparing protein and nucleotide sequence (see *FEMS Microbiol Lett* 1999 174(2): 247-50; *FEMS Microbiol Lett* 1999 177(1): 187-8).

Although the final % homology can be measured in terms of identity, the alignment  
30 process itself is typically not based on an all-or-nothing pair comparison. Instead, a scaled similarity score matrix is generally used that assigns scores to each pairwise comparison based on chemical similarity or evolutionary distance. An example of such a matrix commonly used is the BLOSUM62 matrix - the default matrix for the

BLAST suite of programs. GCG Wisconsin programs generally use either the public default values or a custom symbol comparison table if supplied (see user manual for further details). For some applications, it is preferred to use the public default values for the GCG package, or in the case of other software, the default matrix, such as  
5 BLOSUM62.

Once the software has produced an optimal alignment, it is possible to calculate % homology, preferably % sequence identity. The software typically does this as part of the sequence comparison and generates a numerical result.

10

The sequences may also have deletions, insertions or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent substance. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the  
15 amphipathic nature of the residues as long as the secondary binding activity of the substance is retained. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine, valine, glycine, alanine, asparagine, glutamine,  
20 serine, threonine, phenylalanine, and tyrosine.

Conservative substitutions may be made, for example according to the Table below. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other:

25

ALIPHATIC	Non-polar	G A P
		I L V
	Polar - uncharged	C S T M
		N Q
	Polar - charged	D E
		K R
AROMATIC		H F W Y



Homologous substitution (substitution and replacement are both used herein to mean the interchange of an existing amino acid residue, with an alternative residue) may occur i.e. like-for-like substitution such as basic for basic, acidic for acidic, polar for polar etc. Non-homologous substitution may also occur i.e. from one class of  
 5 residue to another or alternatively involving the inclusion of unnatural amino acids such as ornithine (hereinafter referred to as Z), diaminobutyric acid ornithine (hereinafter referred to as B), norleucine ornithine (hereinafter referred to as O), pyriylalanine, thienylalanine, naphthylalanine and phenylglycine.

10 Replacements may also be made by unnatural amino acids include; alpha\* and alpha-disubstituted\* amino acids, N-alkyl amino acids\*, lactic acid\*, halide derivatives of natural amino acids such as trifluorotyrosine\*, p-Cl-phenylalanine\*, p-Br-phenylalanine\*, p-I-phenylalanine\*, L-allyl-glycine\*,  $\beta$ -alanine\*, L- $\alpha$ -amino butyric acid\*, L- $\gamma$ -amino butyric acid\*, L- $\alpha$ -amino isobutyric acid\*, L- $\epsilon$ -amino  
 15 caproic acid<sup>#</sup>, 7-amino heptanoic acid\*, L-methionine sulfone<sup>#\*</sup>, L-norleucine\*, L-norvaline\*, p-nitro-L-phenylalanine\*, L-hydroxyproline<sup>#</sup>, L-thiopropine\*, methyl derivatives of phenylalanine (Phe) such as 4-methyl-Phe\*, pentamethyl-Phe\*, L-Phe (4-amino)<sup>#</sup>, L-Tyr (methyl)\*, L-Phe (4-isopropyl)\*, L-Tic (1,2,3,4-tetrahydroisoquinoline-3-carboxyl acid)\*, L-diaminopropionic acid <sup>#</sup> and L-Phe (4-  
 20 benzyl)\*. The notation \* has been utilised for the purpose of the discussion above  


---

 (relating to homologous or non-homologous substitution), to indicate the hydrophobic nature of the derivative whereas # has been utilised to indicate the hydrophilic nature of the derivative, #\* indicates amphipathic characteristics.

25 Variant amino acid sequences may include suitable spacer groups that may be inserted between any two amino acid residues of the sequence including alkyl groups such as methyl, ethyl or propyl groups in addition to amino acid spacers such as glycine or  $\beta$ -alanine residues.

### 30 USES

It will be appreciated that the amplified RNA produced in accordance with the present invention represents a useful intermediate for a wide variety of downstream applications.

### cDNA libraries

The amplified RNA may facilitate the construction of complex cDNA libraries from extremely limited amounts of tissue.

5

The amplified RNA can be easily converted into double stranded cDNA using various methods that are well known in the art.

Optionally the double stranded cDNA that is generated may be inserted into a  
10 vector. This allows the recombinant DNA molecules comprising the cDNA library to be introduced into host cells – such as eukaryotic and prokaryotic hosts.

### Ribonucleotide probes

The amplified RNA may also be used for the production of specific ribonucleotide  
15 probes without prior cDNA cloning into riboprobe vectors.

### Subtractive hybridisation

Furthermore, the amplified RNA provides a source of large amounts of single-stranded, anti-sense material for use as driver in subtractive hybridization. For  
20 example, two nucleic acid populations, one sense, and one anti-sense, may be allowed to mix together with one population present in molar excess (driver). Sequences present in both populations will form hybrids, whereas sequences present in only one population remain single-stranded. Thereafter, various well known techniques are used to separate the unhybridised molecules representing  
25 differentially expressed sequences. Accordingly, the amplified RNA may also be applied to improve methods of detecting and isolating nucleic acid sequences that vary in abundance among different populations, such as in comparing mRNA expression among different tissues or within the same tissue according to physiologic state. Examples of subtractive hybridisation technologies include  
30 Suppression Subtractive Hybridisation technology (US 5,565,340), representation difference analysis (US 5,436,142); and linker capture subtraction (Anal. Biochem. (1996) 237:109-114).

### Anti-sense RNA

Anti-sense RNA has a wide variety of uses in both analytical research and therapeutics. Anti-sense RNA functions in several prokaryotic systems to regulate gene expression. Similarly, anti-sense RNA can regulate the expression of many eukaryotic genes. This permits blocking expression of undesirable genes. Therapeutic use of anti-sense RNA therefore involves *in vitro* synthesis of anti-sense RNA with subsequent introduction into the subject (see, generally, Melton, Antisense RNA and DNA, Cold Spring Harbor (1988)).

### 10 Arrays

The application of array technology is often limited because substantial amounts of RNA are required for target preparation. The present invention is therefore particularly suited to the generation of targets for array – such as microarray analysis, in particular, Affymetrix arrays.

15

Array technology and the various techniques and applications associated with it are described generally in numerous textbooks and documents. These include Lemieux *et al.*, (1998), *Molecular Breeding* 4, 277-289, Schena and Davis. *Parallel Analysis with Biological Chips*. in *PCR Methods Manual* (eds. M. Innis, D. Gelfand, J. Sninsky), Schena and Davis, (1999), *Genes, Genomes and Chips*. In *DNA Microarrays: A Practical Approach* (ed. M. Schena), Oxford University Press, Oxford, UK, 1999), *The Chipping Forecast* (*Nature Genetics* special issue; January 1999 Supplement), Mark Schena (Ed.), *Microarray Biochip Technology*, (Eaton Publishing Company), Cortes, 2000, *The Scientist* 14[17]:25, Gwynne and Page, *Microarray analysis: the next revolution in molecular biology*, *Science*, 1999 August 6; and Eakins and Chu, 1999, *Trends in Biotechnology*, 17, 217-218.

### Detection

In a further aspect, the methods of the present invention may be used to identify one or more sequences in a sample by detecting the amplified sequences in the amplified RNA.

### Differential amplification

In a further aspect, the present invention may be used for the detection of differentially expressed genes. It is therefore useful for determining the relative levels of a given sequence relative to other sequences.

5

Such methods may be particularly useful in, for example, molecular diagnostics, where diagnosis is not based upon the presence or absence of a sequence, but on the relative levels of a given sequence.

### 10 KITS

The materials for use in the methods of the present invention are ideally suited for preparation of kits.

Such a kit may comprise containers, each with one or more of the various reagents  
15 (typically in concentrated form) utilised in the methods, including, for example, buffers, the appropriate nucleotide triphosphates (e.g., dATP, dCTP, dGTP and dTTP; or rATP, rCTP, rGTP and UTP), reverse transcriptase, DNA polymerase, RNA polymerase, and one or more oligonucleotides of the present invention.

20 Oligonucleotides in containers can be in any form, e.g., lyophilized, or in solution (e.g., a distilled water or buffered solution), etc. Oligonucleotides ready for use in the same amplification reaction can be combined in a single container or can be in separate containers.

25 The kit optionally further comprises in a separate container an RNA polymerase specific to the RNA polymerase promoter, and/or a buffer for PCR, and/or a DNA polymerase.

The kit optionally further comprises a control nucleic acid.

30

A set of instructions will also typically be included.

GENERAL RECOMBINANT DNA METHODOLOGY TECHNIQUES

The present invention employs, unless otherwise indicated, conventional techniques of chemistry, molecular biology, microbiology, recombinant DNA and immunology, which are within the capabilities of a person of ordinary skill in the art. Such techniques are explained in the literature. See, for example, J. Sambrook, E. F. Fritsch, and T. Maniatis, 1989, *Molecular Cloning: A Laboratory Manual*, Second Edition, Books 1-3, Cold Spring Harbor Laboratory Press; Ausubel, F. M. et al. (1995 and periodic supplements; *Current Protocols in Molecular Biology*, ch. 9, 13, and 16, John Wiley & Sons, New York, N.Y.); B. Roe, J. Crabtree, and A. Kahn, 1996, *DNA Isolation and Sequencing: Essential Techniques*, John Wiley & Sons; M. J. Gait (Editor), 1984, *Oligonucleotide Synthesis: A Practical Approach*, Irl Press; and, D. M. J. Lilley and J. E. Dahlberg, 1992, *Methods of Enzymology: DNA Structure Part A: Synthesis and Physical Analysis of DNA* Methods in Enzymology, Academic Press. Each of these general texts is herein incorporated by reference.

15

The invention will now be further described by way of Examples, which are meant to serve to assist one of ordinary skill in the art in carrying out the invention and are not intended in any way to limit the scope of the invention.

20 EXAMPLESExample 1

---

*Materials and Methods*

BD Biosciences Clontech's SMART™ technology allows PCR amplification of 1st strand DNA by incorporating a priming site at the 5' and 3' ends via the template switching mechanism. The primer (SEQ ID No. 1):

5'AAGCAGTGGTATCAACGCAGAGTggccagtgaattgtaatacgactcactatagggaggcg  
g(T)<sub>30</sub>VN-3'

30 a 94-mer, is used to prime cDNA synthesis. The upper case region at the 5' end, is identical to the 5' PCR Primer II A provided in BD Biosciences Clontech's SMART™ PCR cDNA Synthesis Kit and this sequence generates the 3' anchor on the cDNA for subsequent PCR amplification.. The lower case region is identical to

the T7 promoter sequence currently used in the Affymetrix cDNA synthesis primer. The T7 promoter sequence is added to allow the generation of labelled cRNA targets by *in vitro* transcription. The (T)30 region will bind to poly A tail of messenger RNAs and the 3'-terminal VN clamp (where V is A, G, or C and N is any base) helps ensure priming of mRNA. This oligonucleotide was purified by polyacrylamide gel electrophoresis before use.

“SMART™ II A” Oligonucleotide (10 uM, BD Biosciences Clontech) (SEQ ID No. 2):

10

5'-AAGCAGTGGTATCAACGCAGAGTACGCGGG-3'

and “5' PCR Primer II A” (10 uM, BD Biosciences Clontech) (SEQ ID No. 3):

15 5'-AAGCAGTGGTATCAACGCAGAGT-3'

are identical sequence to those in BD Biosciences Clontech's SMART™ PCR cDNA Synthesis Kit.

20 All reactions are performed in 0.2ml thin-walled PCR tubes.

### RNA

The RNA used in these studies was prepared using guanidinium thiocyanate method [Chirgwin *et al*, (1987)], with all the usual precautions for handling RNA. Cytoplasmic RNA or PolyA+ RNA could also be used in this technique. Integrity of total RNA should be checked by analysis of a sample on RNA gel electrophoresis (eg formaldehyde/ agarose gel), or Agilent LabChip. For mammalian total RNA, two bands at approximately 4.5 and 1.9 kb should be visible; these bands represent 28S and 18S ribosomal RNA respectively, and the ratio of intensities of these bands should be 1.5–2.5:1. RNA purification kits for microscale RNA preparation are available from a number of commercial suppliers (for example Absolutely RNA™

30

Nanoprep, Stratagene; PicoPure<sup>TM</sup>, Arcturus; RNeasy®, Qiagen; RNAqueous<sup>TM</sup> Microkit, Ambion).

Total RNAs for the studies reported here were isolated from two human bladder  
5 tumour biopsies that were obtained from an external collaboration between  
AstraZeneca and Institut Curie, Paris and Henri Mondor Hopital, Creteil, Paris.  
These bladder transitional cell carcinoma biopsies were from a T3 grade 3 (sample  
384) and a superficial Ta grade 1 (sample 842). Bladder biopsies were surgically  
removed by transurethral resection by Dominique Chopin at Henri Mondor Hopital,  
10 Creteil, Paris. Samples were immediately snap-frozen in liquid nitrogen and then  
stored at -80oC until RNA extraction. Total RNA was purified by guanidinium  
thiocyanate extraction followed by cesium chloride gradient ultracentrifugation  
(Chirgwin et al, (1987)) at Institut Curie, Paris, quantitated by A260 measurement  
and the integrity checked by RNA gel electrophoresis. Total RNAs were treated with  
15 RNase-free DNaseI (Ambion, DNA-free<sup>TM</sup> kit) according the manufacturers  
instructions such that final concentrations were 1ug/ul. . As a reference, the targets  
were also prepared following the standard protocol (Affymetrix *GeneChip®*  
*Expression Analysis Technical Manual*) starting with 9ug of the same total RNAs.

20 DNase I-treated total RNAs were then diluted with RNase-free water, and 5ng or  
50ng of total RNA were then used in each amplification reaction.

---

4 RNA control sense polyA+ spikes were added to the total RNAs using a (20x)  
stock consisting of Lys, Phe and Thr from B.subtilis (ATCC) and kanamycin  
25 positive control polyA+RNA (Promega Corporation, Cat C1381). Plasmids for Lys,  
Phe and Thr were obtained from ATCC [pGIBS-Lys, ATCC 87482; pGIBS-Phe,  
ATCC 87483; and pGIBS-Thr ATCC 87484] and sense RNA transcripts were  
generated and purified as described in Affymetrix *GeneChip®* Expression Analysis  
Technical Manual [<http://www.affymetrix.com/>].

30

Lys, Phe, Thr and kanamycin spikes were added at final concentrations of 1, 5, 20  
and 1pM respectively to the non-amplified RNA samples.

Table (1) gives a summary of the probes synthesised and their respective cRNA yields. Note that for the conventional Affymetrix standard protocol, RNA / T7(dT)24 annealing was undertaken in the absence of dNTPs, which were subsequently added to the first strand master mix.

5

#### *SMART<sup>TM</sup> 1st strand cDNA syntheses*

The first and the second strand synthesis are performed in the same tube that enhances the synthesis procedure and maximizes recovery of cDNA. The method  
10 described here uses PowerScript<sup>TM</sup> Reverse Transcriptase (BD Biosciences Clontech), a point mutant of Moloney murine leukemia virus (MMLV) reverse transcriptase. PowerScript<sup>TM</sup> lacks RNase H activity, but retains wild-type polymerase activity, so longer cDNA fragments can be synthesized than wild-type MMLV RT.

15

The recommended SMART<sup>TM</sup> protocol (BD Biosciences Clontech) was modified by including 1 mM dNTP's in the initial step in the procedure where the RNA is heated to 70°C for 2 min. We show here that this modification increased the yield of cRNA, from defined amounts of starting Total RNA (see Table 2 below). This modification  
20 allows a reduced number of PCR cycles with limited starting material, and should help minimize any distortions to the mRNA distribution.

cRNAs synthesised from 50ng or 5ng total RNA. 1mM dNTPs were added at the RNA-primer annealing step plus the cDNA synthesis mix [dNTPs in steps 1 and 2],  
25 or only in the cDNA synthesis mix [dNTPs in step 2 only]. The numbers of PCR cycles required to subsequently generate ~ 20µg of cRNA are shown in Table 2. Primer mix was prepared by mixing equal volumes of 1µM SMART<sup>TM</sup>-T7-oligo(dT)30VN oligonucleotide SEQ ID 1 and 1µM SMART<sup>TM</sup> II A oligonucleotide SEQ ID 2 (BD Biosciences Clontech) so that both were 0.5µM. We have used a  
30 reduced concentration of both primers [Baugh, et al (2001)] reported that reduced concentrations of oligo dT primer reduced non-specific artifacts when using lower amounts of template RNA, and we reasoned that reduced concentrations of the novel primer SMART<sup>TM</sup>-T7-oligo(dT)30VN oligonucleotide SEQ ID 1 and of SMART<sup>TM</sup>



II A oligonucleotide SEQ ID 2 would be required as we are starting with much less total RNA than required in the standard SMART<sup>TM</sup> protocol.

3µl of Total RNA were mixed with 2µl of 0.5µM primer mix. RNA / primer was  
5 heated at 70°C for 2 min, then at 4°C for 5 min in a thermal cycler.

At 4°C, 5µl of First Strand Mastermix was added to each reaction. First Strand Mastermix was prepared from components of SMART<sup>TM</sup> PCR cDNA Synthesis Kit (BD Biosciences Clontech, # K1052-1) and 2µl 5x First-strand buffer (250mM Tris-HCl, pH8.3, 30mM magnesium chloride and 375mM potassium chloride), 1µl  
10 20mM dithiothreitol (DTT), 1µl 10mM dNTPs (10mM each dATP, dCTP, dGTP, dTTP), 1µl PowerScript<sup>TM</sup> Reverse Transcriptase was added. Reactions were mixed by gentle pipetting, then heated for 1h at 42°C, then 4°C for 5 min in a thermal cycler.

15

#### *PCR Amplification of SMART<sup>TM</sup> synthesised cDNA*

The method described here uses Advantage® 2 Polymerase Mix (BD Biosciences Clontech), which allows efficient and accurate amplification of cDNA templates by  
20 long-distance PCR [Barnes, 1994]. Advantage<sup>TM</sup> 2 products are described in US 5,436,149.

---

The Advantage® 2 Polymerase Mix contains TITANIUM<sup>TM</sup> Taq DNA Polymerase, a nuclease-deficient N-terminal deletion of Taq DNA Polymerase, and a minor  
25 amount of a proofreading polymerase. Advantage® 2 Polymerase Mix also contains TaqStart<sup>TM</sup> Antibody (BD Biosciences Clontech) to provide automatic hot-start PCR (Kellogg et al., 1994) and reduce non-specific priming of template. This combination allows efficient amplification of full-length cDNAs with a significantly lower error rate than that of conventional PCR (Barnes, 1994).

30

90µl PCR Master Mix was added to each cDNA synthesis using the same tube as for SMART<sup>TM</sup> cDNA synthesis. 5' PCR IIA primers SEQ ID 3 was identical sequence to that used in the BD Biosciences Clontech SMART<sup>TM</sup> cDNAsynthesis kit (Cat #

K1052-1). This primer will bind to both ends of the SMART<sup>TM</sup> cDNA and allow PCR amplification. PCR was set up using components from Advantage<sup>®</sup> 2 polymerase Kit (BD Biosciences Clontech, Cat# 8430-1) with 10ul 10X Advantage<sup>®</sup> 2 PCR Buffer (40mM Tricine-KOH, pH9.2, 15mM potassium acetate, 3.5 mM magnesium acetate), 2ul 50X dNTP Mix (10 mM of each dNTP), 2ul 10uM 5' PCR Primer II A SEQ ID 3, and 2ul 50X Advantage<sup>®</sup> 2 Polymerase Mix and 74ul water.

Thermal cycling parameters of the PCR reactions were 60 sec at 95°C for hot start, followed by 3 step cycling for a pre-determined numbers of cycles (eg 11 cycles for 50ng starting total RNA or 15 cycles for 5ng total RNA) of denaturation for 15 sec at 95°C, annealing for 30 sec at 65°C, and extension for 6 min at 68°C. Reactions were then held at 4°C in the thermal cycler until purification. 50ng reactions were typically cycled for 10 or 11 cycles, and 5ng reactions for 14 or 15 cycles.

15

We have devised an improved method for determining the optimal number of PCR cycles that are required from a given amount of starting material. For any PCR-based method one of the key factors is to perform the minimum numbers of PCR cycles (for a given amount of starting material) that will result in sufficient target for the intended downstream application. If too many cycles are performed, then it is likely that the representation of mRNAs could be biased as the PCR reactions are unlikely to be identical for each RNA template in the complex mixture, and PCR may also reach a plateau. If too few cycles are performed then insufficient PCR product is obtained for subsequent applications. BD Biosciences Clontech SMART<sup>TM</sup> methodology recommends an optimisation strategy that involves examination of the amplified PCR products generated after different numbers of cycles on agarose gel electrophoresis and then visual estimation of the optimal amplification. In the method described here, we determine empirically for a given amount of starting total RNA (eg 50ng or 5ng), the minimum numbers of PCR cycles that are required such that when the entire PCR products are then used for *in-vitro* transcription (IVT) reactions to generate cRNA, we obtain sufficient cRNA for the intended downstream application. This can be done easily by starting with a given amount of total RNA (eg 5ng or 50ng) by setting up identical reactions and

30

performing PCR for defined numbers of cycles (or by removing aliquots from a PCR reaction for analysis and performing additional cycles on the remainder of the PCR reaction). The entire PCR products from each reaction (for example 50ng starting total RNA that has undergone PCR thermal cycling for 9,10,11,12,13 or 14 cycles) is purified and used for IVT. The number of PCR cycles that gives the minimum amount of cRNA that is sufficient for the downstream application is then determined. This number of cycles can then be used routinely for similar studies with other RNA's at the same starting concentrations.

For example, in this study reported here we describe downstream use on Affymetrix GeneChip® probe arrays. If the PCR product was to be used for another downstream application then an identical strategy could be used. The cycling parameters in this protocol have been optimised using a MJ Research PTC200 thermal cycler. However, the numbers of cycles required for different amounts of starting total RNA should be determined empirically in initial experiments as optimal parameters may vary with different templates, thermal cyclers, or if different enzymes are used for cDNA synthesis or PCR. Once the optimal conditions are determined for a specific amount of starting total RNA, then subsequent experiments with this amount of RNA under identical conditions should results in similar yields of product.

20

---

This PCR step can also be enhanced by addition of dNTP's in the initial step in the procedure where the RNA is heated to 70oC for 2 minutes (see above for details).

This means that a reduced number of PCR cycles are required with limited amounts of starting material and therefore help minimise any distortions to the mRNA distributions.

25

PCR products were purified using QIAGEN Qiaquick columns as per manufacturer's instructions. For the elution: 30µl of elution buffer was applied to column and left to stand for 2min prior to centrifugation. Eluted volumes were adjusted to 30µl with molecular biology grade water. PCR purification could be performed using other PCR purification methods or commercial kits.

*Synthesis of Biotin-Labelled cRNA (IVT) from amplified cDNAs*

ENZO ® BioArray™ HighYield™ RNA Transcript Labeling Kit, Affymetrix 900182 was used for IVT, but this could be obtained from a number of other suppliers. To each 30µl of purified PCR was added 20µl of Mastermix. [5µl 10x HY  
5 Reaction Buffer, 5µl 10x Biotin Labelled Ribonucleotides, 4µl 10x DDT, 4µl 10x RNase Inhibitor Mix, 2µl 20x T7 RNA Polymerase]. IVT reactions were incubated at 37°C for 5hrs using thin-walled 0.2ml PCR tubes.

50ul water was added per sample and then the entire reactions were purified using  
10 RNeasy® Mini columns (QIAGEN) as per manufacturer's instructions. Purified RNA was eluted with 2 sequential applications of 50µl RNase-free water i.e. 100µl final volume.

5ul eluted RNA was added to 95ul water per well of a 96-well UV plate (Costar #  
15 3635) and used for A260 measurement (Molecular Devices, Spectramax) to quantitate the amount of RNA.

#### *Fragmentation and Hybridization*

20 Followed the instructions described in the Affymetrix GeneChip® Expression Analysis Technical Manual.

#### **Data Analysis**

25 Data were analysed for a number of assay performance criteria, in order to evaluate the effectiveness of the novel amplification protocol for Affymetrix GeneChip® array expression analysis. These criteria were labelled cRNA yield; Standard array quality metrics including Raw Q, Background, Scaling Factor, Percent Present Calls, and 3' and 5' Signal Intensity ratio of control probe sets; Linearity and sensitivity of  
30 amplification as quantified using spike-in bacterial poly-A controls; Reproducibility; Concordance analysis of differential gene expression between the standard Affymetrix protocol and the novel amplification protocol; Confirmation of gene expression changes by an independent technique (RT-PCR).

### Labelled cRNA Yield

The yield of labelled cRNA is critical because sufficient target needs to be generated for downstream applications for example Affymetrix GeneChip® probe arrays. The required amount of labeled cRNA for Affymetrix GeneChip® is 10–15 µg for each genome array. A series of experiments were carried out using different amounts of starting material. Total RNAs were extracted from a T3 Grade 3 (sample 384) and a superficial Ta Grade 1 (sample 842) transitional cell bladder carcinoma and used as template for preparing probes. Replicate probes were prepared from 9µg total RNA using the conventional Affymetrix protocol and from 50ng and 5ng total RNA using the novel amplification method described here. Table 3 below gives a summary of the probes synthesised, the number of thermocycles used and their respective cRNA yields, and indicates which probes were used for subsequent fragmentation and hybridization to Affymetrix GeneChips. Note that for the conventional probe syntheses oligo dT annealing was undertaken without the presence of dNTPs. The quantity of cRNA obtained was measured by absorbance at 260 nanometers (nm) after purification and are plotted (Figure 2) to demonstrate the repeatability of amplification reactions. As shown in Figure 2, the quantities of the labeled cRNA obtained from samples of 5ng or 50 ng total RNA with the novel amplification protocol were comparable with the range anticipated from the standard protocol.

---

### Standard GeneChip® Array Quality Metrics

To further evaluate whether the novel amplification protocol is suitable for preparing targets for GeneChip® array expression analysis, 10 µg of cRNA targets, generated from the experiments described previously, were hybridized on the GeneChip® Human Genome U133A (HG-U133A) arrays under standard conditions and washed using the EukGE-WS2v4 fluidics protocol. After scanning, the chips were subjected to a visual QC check for excessive background and the presence of staining artefacts. The data were then analyzed using Affymetrix Microarray Suite 5.0 (MAS 5.0) software and various quality control metrics were obtained.

Table 3 gives a summary of the QC metrics taken from the .RPT files. The scaling factors were consistent for all chip hybridisations with no extreme values observed. Raw Q, Background, and Scaling Factor values were examined to evaluate the overall sample quality with the targets prepared according to the two protocols (novel amplification protocol and the standard protocol) (see Fig 3). As shown in Table 4, comparable values were obtained for all three parameters. For example, the Background values were all about 100, as anticipated for typical experiments. The Scaling Factors were also within threefold range—even when comparing the data from 5 ng of starting material amplified with the novel amplification protocol.

10

Affymetrix GeneChip® arrays are designed predominantly with probes selected adjacent to the poly-A tail of the mRNA. This design strategy along with the inherent generation of shorter fragment from additional amplifications may create targets that are skewed to the 3' end. To examine this phenomenon, Affymetrix have created probe sets for specific maintenance genes (e.g., GAPDH, actin), and these probe sets are designed to the 3', middle, and 5' regions of the transcript. The 3' probe set Signal Intensity can then be compared to the 5' probe set Signal Intensity (3'/5' ratio) to evaluate the efficiency of the transcription reaction. As shown in Fig 4 (top and middle), the 5 ng and 50ng total RNA samples with the novel amplification protocol described here, produced the 3'/5' ratio for GAPDH and Actin genes, of approximately 1, which are equivalent to those samples processed with the standard protocol and well within the Affymetrix recommended range of 3. Actin transcript represented on the array was longer than the GAPDH gene, with 1,761 bases (with the 5' probe set within 1178–1712 bases, and the Middle probe set within 589–1117 bases), but the 3'/5' ratios were still maintained. We also calculated the 3'/Middle probe set ratio (3'/M) of the GAPDH and Actin, genes (data not shown) which was also very similar to those samples processed with the standard protocol.

30 The Percent Present Calls comparison was used to globally assess the data representations. As shown in Fig 4 (bottom), comparable Percent Present Call values were obtained with reducing amounts of starting materials. Even at 5 ng of starting

total RNA, about 50 percent of the probe sets were still called as Present by the Affymetrix MAS5.0 software algorithm.

### Linearity and Sensitivity

5

The ability of any amplification protocol to accurately detect differences in expression levels is highly dependent on the assay's linearity and sensitivity.

The novel amplification protocol was evaluated for both parameters by analyzing the  
10 spike-in poly-A control transcripts in a complex sample. 4 spike-in control transcripts were spiked into the complex human bladder biopsy total RNA samples at various concentrations. 3 were *in vitro*-generated bacterial poly-A controls - *lys*, *phe*, and *thr* and the other spike was a commercially available poly-A control RNA for kanamycin. *Lys*, *phe*, and *thr* are represented by probe sets on the U133A  
15 GeneChips and so these spikes can be detected when added to RNA samples for profiling. Kanamycin spike-in poly-A control transcript can be measured by a specific real-time PCR based TaqMan assay. 5 ng and 50 ng of total RNA were labelled with the novel amplification protocol, the target was hybridized on HG-U133A arrays, and the Signal Intensities for the controls were plotted (Figure 5), and  
20 the three transcripts were detected by all the probes regardless of the method.

---

### Reproducibility of replicates

Reproducibility is a key requirement for any amplification protocol, and it is  
25 essential for generating reliable results. Two independent target preparations with 5 ng and 50 ng of two different total RNAs (RNA IDs 384 and 842) using the novel amplification protocol were hybridized to HG-U133A arrays.

Pearson correlation values (Tables 5 and 6) were calculated for the amplified and  
30 non-amplified probes derived from each sample. The Pearson correlation coefficients were all >0.95 thus indicating very good agreement between each set of replicates. However, as the standard and novel amplification protocol use different

total RNA amounts and different protocols, it is not recommended that results obtained from amplified and non-amplified samples are directly compared.

Data sets for each chip hybridisation were clustered using GeneSpring software (Redwood City, CA): the clustering dendrogram (Figure 6) shows that the two samples were clustered separately and that, as expected, within each sample the amplified probes were distinguishable from the non-amplified probes

### Scatter plots of the replicates

Log scale scatter plots for replicate samples (Figure 7) indicate typical profiles about the xy diagonal which was indicative of good reproducibility for the replicates. Most of the scatter was noticeable at signal values  $<500$ ; this is due to mainly to the limitations of the technology platform and is independent of probe synthesis method.

### Data analysis

The numbers of genes changing by more than 2 fold in any direction were identified using Spotfire software (Goteborg, Sweden) and summarised in Tables 7 and 8. Log scale scatter plots in Figure 8 indicate genes changing  $>2$  fold (equivalent to  $> |\log_{10} 0.3|$ ).

We have compared scatter plots of all the log ratio sets of all the pairwise comparisons of non-amplified versus amplified samples to obtain a measure of relative gene expression for the samples being compared. Figure 9 shows that for all the log ratio sets, when compared to Set A, they are positioned similarly along the xy diagonal. As a qualitative observation, it is reasonable to assume that the ratios sets are all alike – indeed the ratios derived from the novel amplification method are no more different than the Set A versus Set B comparison where all data was obtained using standard protocol. The Pearson correlation coefficients vary from 0.81 to 0.87 with the highest figure reported for the comparison between non-amplified probes and the lowest figure of 0.81 reported for Set A versus Set F. – these are all good correlation values for log ratio comparisons. Note that the data



presented in Figure 9 were filtered to remove noise i.e. for any given gene where signals were <100 across all twelve GeneChip® hybridisations. Table 4 shows that the average background signal reported for this experiment was  $110 \pm 22$  SD.

5 Table 6 & Figure 8 show that there were similar numbers of genes changing >2 fold for each comparison between samples 384 and 842 (average =  $7844 \pm 444$  SD) regardless of the probe synthesis method. In order to determine how many of these changes are for the same genes in each set, Set A was used as the reference because these data were obtained using standard Affymetrix protocol. However, by taking  
10 the comparison of Set A versus all other sets (Table 6) it can be seen that the number of genes in common is less than the figure of 7844 reported above, and that this includes Set A versus Set B where all data were obtained using standard Affymetrix protocol. Furthermore, it can be seen that there were only 2385 genes in common across all five comparisons to Set A. This result is at least in part due to the  
15 limitation of setting an arbitrary cut off value (in this case >2 fold).

k-means clustering was employed on the data sets using Spotfire software with default settings and arbitrarily chosen to calculate 70 clusters. The data sets were left intact with no background signal filtering employed. The frequency histograms  
20 (Figure 10) depict the numbers of genes in each cluster and whether they were changing >2 fold in which case they are coloured blue. Note that the largest cluster contains 5488 genes, and that the first four clusters comprise approximately 60% of all genes. Collectively the blue clusters in the lower histogram represent the 2385 genes changing >2 fold in common – see Table 7.

25

Attention will now be paid to selected clusters so as to illustrate that the gene transcript profiles can be accurately captured using the CPA method. Firstly, some pointers to help with analysis of the clusters presented in Figure 12 (all genes), Figure 13 (genes <2 fold) and Figure 14 (genes >2 fold):-

30

- clusters are numbered consecutively, left to right, proceeding downwards, from 1 to 70 (the cluster title bar should just about be legible when printed about)

- y axis of each cluster is  $\log_{10}$  scale
- x axis is represented in this order, left to right: 384 5ng rep1, 384 50ng rep2, 384 5ng rep1, 384 5ng rep2, 384 9 $\mu$ g rep1, 384 9 $\mu$ g rep2, 842 5ng rep1, 842 50ng rep2, 842 5ng rep1, 842 5ng rep2, 842 9 $\mu$ g rep1, 842 9 $\mu$ g rep2
- data points 1-6 should be similar horizontally or data points 7-12 should be similar horizontally

As an example, regarding the intentionally made sparse clusters in Figure 11 we can say that:-

- o cluster 1 signals show no pattern and are low in magnitude i.e. <100
  - o cluster 2 one gene down-regulated in 842, other gene shows no alteration
  - o cluster 3 gene shows no meaningful alteration between samples
  - o cluster 4 one gene up-regulated in 842, other gene shows no alteration
  - o cluster 5 three genes down-regulated in 842
  - o cluster 6 no discernible pattern
  - o cluster 7 no change in gene expression
  - o cluster 8 as for cluster 7
  - o cluster 9 three genes down-regulated in 384
- Looking at the clusters generally (Figure 12) it can be seen that there are some odd shaped ones including the “W” shapes in clusters 27, 48, and 62. However the log ratios reported for these genes, which are often ribosomal in nature, do not indicate any differential gene expression – and from a biological perspective this is consistent because the ribosomal species are not expected to vary significantly anyway, and this is likely to be artefact of the novel amplification protocol whereby some amplification of non-polyadenylated ribosomal RNAs is occurring but which in the authors’ opinion can be considered to have an entirely neutral impact on the data: it is the gene expression ratios that are important. Moreover we can take into

consideration the fact that the total numbers of these genes are very small, and that they are nearly all coloured red i.e. changing  $<2$  fold - it is left to the reader to refer to the histograms in Figure 10 to confirm these facts. As stated previously the first four clusters comprise about 60% of the genes on the GeneChip® and in the case of  
5 cluster 1 all the genes demonstrate very low signal magnitudes ( $\sim <100$ ). This is very close to the detection threshold of the Affymetrix technology and signals in this region may or may not be due to real gene expression regardless of the method of probe synthesis. Figure 11 shows clearly genes demonstrating meaningful changes in expression, and which behave similarly for the novel amplification protocol and  
10 Affymetrix standard protocol derived data, will be of the shapes in the example clusters numbered 5 and 9. Now by inspecting the main body of data by referral to Figure 13, which shows clusters containing genes changing  $>2$  fold, it is obvious that that for the majority of data where differential expression occurs then the novel amplification protocol and Affymetrix standard protocols are very alike. It is this  
15 qualitative analysis, along with the scatter plots of log ratios and the QC metrics, which demonstrate that the novel amplification protocol can generate transcript profiles from 5-50ng total RNA with acceptable maintenance of profile integrity.

Several gene changes have been confirmed by RT-PCR using the same Total RNAs  
20 (384 and 842) and are concordant with Affymetrix GeneChip® results (data not shown).

---

## Conclusions

25 We found that the novel amplification protocol is suitable for robustly amplifying and labelling as low as 5 ng of total RNA for expression profiling. The assay demonstrated good cRNA yield, sensitivity, and reproducibility. In the work exemplified here we have focused downstream application of the cRNA, that is generated via the novel amplification method, for Affymetrix GeneChip® probe  
30 arrays. However, the cRNA could be used for other downstream applications, including other gene expression profiling platforms. The results closely approximate the standard Affymetrix method thus maintaining the integrity of the transcript profile and the QC metrics are comparable to those obtained using standard protocol.

The protocol provides scope for further improvement in particular the number of thermocycles could be reduced further still so that the final yield of biotinylated cRNA is approximately 10µg since this is the minimum quantity actually required for hybridisation to an Affymetrix GeneChip®.

5

As described here, there is also scope to use lower amounts of total RNA.

All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and  
10 system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for  
15 carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

20

Table 1

Sample	Addition of dNTPs during annealing	Method
384 50ng amp rep1	yes	15 cycles PCR + IVT
384 50ng amp rep2	yes	15 cycles PCR + IVT
384 5ng amp rep1	yes	11 cycles PCR + IVT
384 5ng amp rep2	yes	11 cycles PCR + IVT
384 9µg non-amp rep1	no	IVT only
384 9µg non-amp rep2	no	IVT only
842 50ng amp rep1	yes	15 cycles PCR + IVT
842 50ng amp rep2	yes	15 cycles PCR + IVT
842 5ng amp rep1	yes	11 cycles PCR + IVT
842 5ng amp rep2	yes	11 cycles PCR + IVT
842 9µg non-amp rep1	no	IVT only
842 9µg non-amp rep2	no	IVT only

---

**Table 2**

The effect of dNTP addition at the primer-annealing step on yield of cRNA

Starting Total RNA	dNTPs in step 2 only	dNTPs in steps 1 and 2
50ng Total RNA	12	10
5ng Total RNA	16	14

Table 3

Probe syntheses cRNA yield and number of thermocycles used.

No.	sample	PCR cycles	IV T	Yield cRNA ( $\mu$ g)	
1	50ng 842 rep1	10	Ye s	20	Not used
2	50ng 842 rep2	10	"	21	"
3	50ng 842 rep1	11	"	37	Used for fragmentation + hyb
4	50ng 842 rep2	11	"	36	"
5	50ng 384 rep1	10	"	21	Not used
6	50ng 384 rep2	10	"	20	"
7	50ng 384 rep1	11	"	31	Used for fragmentation + hyb
8	50ng 384 rep2	11	"	32	"
9	5ng 842 rep1	14	"	18	Not used
10	5ng 842 rep2	14	"	17	"
11	5ng 842 rep1	15	"	30	Used for fragmentation + hyb
12	5ng 842 rep2	15	"	28	"
13	5ng 384 rep1	14	"	21	Not used
14	5ng 384 rep2	14	"	16	"
15	5ng 384 rep1	15	"	26	Used for fragmentation + hyb
16	5ng 384 rep2	15	"	28	"
17	842 9 $\mu$ g rep1	0	"	80	"
18	842 9 $\mu$ g rep2	0	"	85	"
19	384 9 $\mu$ g rep1	0	"	87	"
20	384 9 $\mu$ g rep2	0	"	91	"

**Table 4**  
**Array Quality Metrics Comparisons**

<b>sample</b>	<b>Raw Q</b>	<b>*Background d</b>	<b>Scaling Factor</b>	<b>gapdh 3'/5'</b>	<b>actin 3'/5'</b>
384 50ng amp rep1	4.32	115.14	1.96	0.80	0.97
384 50ng amp rep2	4.06	97.83	2.43	0.96	0.78
384 5ng amp rep1	4.10	92.74	2.66	1.01	0.84
384 5ng amp rep2	5.99	172.10	1.94	1.03	0.91
384 9µg non-amp rep1	4.16	99.42	1.99	0.86	1.08
384 9µg non-amp rep2	5.00	116.93	2.00	1.10	1.11
842 50ng amp rep1	4.41	108.02	2.35	0.97	0.92
842 50ng amp rep2	4.13	98.75	2.30	0.96	0.82
842 5ng amp rep1	4.04	98.89	2.57	0.88	0.83
842 5ng amp rep2	3.94	94.44	2.30	0.94	0.86
842 9µg non-amp rep1	4.26	99.84	2.75	0.91	0.96
842 9µg non-amp rep2	5.00	129.86	2.25	0.92	1.06

5 \*Average Background =  $110 \pm 22$  SD

The targets generated from the standard protocol or the novel amplification protocol were hybridised to U133A Human Genome Genechips under standard conditions and washed using the EukGE-WS2v4 fluidics protocol. Table 2 gives a summary of the QC metrics taken from  
 10 the Affymetrix MAS5.0 .rpt files. All of the metrics are within the acceptable range of values.



**Table 5**

Pearson correlation matrix for the biopsy "842" samples compared against each other.

Sample 842	50ng amp r1	50ng amp r2	5ng amp r1	5ng amp r2	9µg non- amp r1	9µg non- amp r2
50ng amp r1	1.00					
50ng amp r2	0.99	1.00				
5ng amp r1	0.99	0.99	1.00			
5ng amp r2	0.99	0.99	0.99	1.00		
9µg non- amp r1	0.95	0.95	0.95	0.95	1.00	
9µg non- amp r2	0.96	0.95	0.95	0.95	0.99	1.00

5

**Table 6**

Pearson correlation matrix for the biopsy "384" samples compared against each other.

Sample 384	50ng amp r1	50ng amp r2	5ng amp r1	5ng amp r2	9µg non- amp r1	9µg non- amp r2
50ng amp r1	1.00					
50ng amp r2	0.98	1.00				
5ng amp r1	0.98	0.99	1.00			
5ng amp r2	0.98	0.99	0.99	1.00		
9µg non- amp r1	0.96	0.96	0.96	0.95	1.00	
9µg non- amp r2	0.96	0.96	0.96	0.96	0.99	1.00

10

**Table 7**

Genes changing >2 fold for each set of replicates.

5

Set	Comparison	Genes changing > 2 fold
A	9µg 384 non amp rep1 versus 9µg 842 non amp rep1	7440
B	9µg 384 non amp rep2 versus 9µg 842 non amp rep2	7477
C	50ng 384 amp rep1 versus 50ng 842 amp rep1	7620
D	50ng 384 amp rep2 versus 50ng 842 amp rep2	7744
E	5ng 384 amp rep1 versus 5ng 842 amp rep1	8508
F	5ng 384 amp rep2 versus 5ng 842 amp rep2	8275

**Table 8**

10 Intersection of sets demonstrating number of gene expression changes in common for each pairwise comparison

Set comparisons	> 2 fold common to both sets	Common to all 5 comparisons
A and B	4737	
A and C	4661	
A and D	4738	2385
A and E	4803	
A and F	4678	

15

SEQUENCESSEQ ID No 1

5 5'AAGCAGTGGTATCAACGCAGAGTGGCCAGTGAATTGTAATACGACTCA  
CTATAGGGAGGCGG(T)<sub>30</sub>VN-3'

where V is A, G , or C and N is any base

10

SEQ ID No. 2 (described in US 5,962,271 and US 5,962,272)

5'-AAGCAGTGGTATCAACGCAGAGTACGCGGG-3'

15 SEQ ID No. 3 (described in US 5,962,271 and US 5,962,272)

5'-AAGCAGTGGTATCAACGCAGAGT-3'

SEQ ID No 4

20

5'AAGCAGTGGTATCAACGCAGAGTAATACGACTCACTATAGGGAGA(T)<sub>24</sub>  
VN-3'

---

wherein V is A, G , or C and N is any base.

25

SEQ ID No. 5

5' GCATTAACCCTCACTAAC 3'

30 SEQ ID No. 6

5' TAATACGACTCACTATA 3'

SEQ ID No. 7

5' AATACGACTCACTATAGGGAGA 3'

5 SEQ ID NO. 8

5' GGCCAGTGAATTGTAATACGACTCACTATAGGGAGGCGG 3'

SEQ ID No. 9

10

5' ATTTAGGTGACACTATA,3'

REFERENCES

- Assersohn, L, Gangi, L, Zhao, Y, Dowsett, M, Simon, R, Powles, TJ, Liu, ET (2002)  
The feasibility of using fine needle aspiration from primary breast cancers for cDNA  
5 microarray analyses. *Clin Cancer Res* ,8:794-801
- Van Gelder, RN, von Zastrow, ME, Yoo, I A, Dement, WC, Barchas, JD, Eberwine,  
JH (1990) Amplified RNA synthesized from limited quantities of heterogeneous  
cDNA. *Proc Natl Acad Sci USA*, 87, 1663-1667
- 10 Eberwine, J, Yeh, H, Miyashiro, K, Cao, Y, Nair, S, Finnell, R, Zettel, M, Coleman,  
P (1992) Analysis of gene expression in single live neurons. *Proc Natl Acad Sci  
USA* 89, 3010-3014
- 15 Phillips, J, and Eberwine, JH (1996) Antisense RNA amplification: a linear  
amplification method for analyzing the mRNA population from single living cells.  
*Methods* 10:283-288
- Affymetrix GeneChip® Expression Analysis Technical Manual available at  
20 <http://www.affymetrix.com>.
- 
- Mahadevappa, M, & Warrington, J (1999) A high-density probe array sample  
preparation method using 10-to 100-fold fewer cells. *Nat Biotechnol* 17, 1134-1136
- 25 Pabón, C, Modrusan, Z, Ruvolo, MV, Coleman, IM, Daniel, S, Yue, H, Arnold, LJ  
Jr, Reynolds, MA (2001) Optimized T7 amplification system for microarray  
analysis. *Biotechniques* 31, 874-879
- Luo, L, Salunga, RC, Guo, H, Bittner, A, Joy, KC, Galindo, JE, Xiao, H, Rogers,  
30 KE, Wan, JS, Jackson, MR (1999) Gene expression profiles of laser-captured  
adjacent neuronal subtypes. *Nat Med* 5, 117-122

Ohshima, H., Zhang, X., Kohno Y., Alevizos, I., Posner M., Wong DT, Todd R: (2000) Laser capture microdissection-generated target sample for high-density oligonucleotide array hybridization. *Biotechniques*, 29, 530-536

- 5 Affymetrix Technical Note GeneChip ® Eukaryotic Small sample Target Labeling Assay Version II [<http://www.affymetrix.com/Download/manuals>]

Luzzi, V., Holtschlag, V., Watson, MA (2001) Expression Profiling of ductal carcinoma in situ by laser capture microdissection and high-density oligonucleotide  
10 arrays. *Am. J. Pathology*, 158, 2005-2010

Wang E, Miller LD, Ohnmacht, GA, Liu ET, Marincola, FM (2000) High-fidelity mRNA amplification for gene profiling. *Nat. Biotechnol.* 18, 457-459.

- 15 Hu L, Wang J, Baggerly K, Wang H, Fuller GN, Hamilton SR, Coombes KR, Zhang W (2002) Obtaining reliable information from minute amounts of RNA using cDNA microarrays. *BMC Genomics*, 3, 16

Akowicz, A. and Manuelidis, L. (1989) A novel cDNA/PCR strategy for efficient  
20 cloning of small amounts of undefined RNA. *Gene* 81, 295-306

Belyavsky, A., Vinogradova, T. and Rajewsky, K. (1989) PCR-based cDNA library construction : general cDNA libraries at the level of a few cells *Nucleic Acids Res.*  
17, 2919-2932

25

Domec, C, Garbay, B., Fournier, M. Bonnet, J. (1990) cDNA library construction from small amounts of unfractionated RNA : association of cDNA synthesis with polymerase chain reaction amplification. *Anal Biochem.* 188, 422-426

- 30 Brady, G., Barbara, M., Iscove, N., (1990). Representative in vitro cDNA amplification from individual hematopoietic cells and colonies. *Methods Mol. Cell Biol.* 2, 17-25

Apte, A.N., and Siebert, P.D. (1993) Anchor-ligated cDNA libraries : a technique for generating a cDNA library for the immediate cloning of the 5'ends of mRNAs. *Biotechniques*, 15, 890-893

- 5 Fromont-Racine, M.A., Bertrand, R., Pictet, R., and Grange, T. (1993). A highly sensitive method for mapping the 5' termini of mRNAs. *Nucleic Acids Res.* 21, 1683-1684

- Kato, S, Sekine, S., Oh, S.W., Kim, N.S., Umezawa, Abe, N., Yokoyama-  
10 Kobayashi, M. and Aoki, T. (1994) Construction of a human full-length cDNA bank. *Gene* 150, 243-250

Maruyama, K. Sugano, S. (1994) Oligo-capping : a simple method to replace the cap structure of eukaryotic mRNAs with oligonucleotide. *Gene* 138, 171-174

15

Frohman, M.A., Dush, M.K. and Martin, G.R. (1988) Rapid production of full-length cDNAs from rare transcripts : amplification using a single gene-specific oligonucleotide primer. *Proc. Natl. Acad. Sci. USA* 85, 8998-9002]

- 20 Chenchik, A., Zhu, Y. Y., Diatchenko, L., Li, R., Hill, J. & Siebert, P. D. (1998) Generation and use of high-quality cDNA from small amounts of total RNA by SMART<sup>TM</sup> PCR. In *Gene Cloning and Analysis by RT-PCR* (BioTechniques Books, MA), pp. 305-319

- 25 SMART<sup>TM</sup> RACE cDNA Amplification Kit (January 1999) CLONTECHniques XIV (1), 4-6

- Zhu, Y.Y., Machleder, E. M., Chenchik, A., Li, R. & Siebert, P. M. (2001) Reverse transcriptase template switching: A SMART<sup>TM</sup> approach for full-length cDNA  
30 library construction. *BioTechniques* 30, 892-897.

Rappolee, D.A., Wang, A., Mark, D., Werb, Z., 1989. Novel method for studying mRNA phenotypes in single or small numbers of cells. *J. Cell Biochem.* 39, 1.

Cheng, T., Shen, H., Giokas, D., Gere, J., Tenen, D.G., Scadden, D.T., (1996). Temporal mapping of gene expression levels during the differentiation of individual primary hematopoietic cells. *Proc. Natl. Acad. Sci. USA.* 93, 13158.

5

O'Brien, D.P., Billadeau, D., Van Ness, B., (1994). RT-PCR assay for detection of transcripts from very few cells using whole cell lysates. *Biotechniques* 16, 586

Theilgaard-Monch, K, Cowland, J., Borregaard, N. (2001) Profiling of gene expression in individual hematopoietic cells by global mRNA amplification and slot blot analysis. *J. Immunol. Methods* 252, 175-189

Iscove, N.N., Barbara, M., Gu, M., Gibson, M., Modi, C., & Winegarden, N. (2002) Representation is faithfully preserved in global cDNA amplified exponentially from sub-picogram quantities of mRNA *Nat Biotechnol.* 20, 940 – 943

Dixon, A., Richardson, K., Lee, P.J., Carter, K., Freeman, T.C. and Freeman, N.P. (1998) Expression profiling of single cells using three prime end amplification (TPEA) PCR *Nucl. Acids Res.* 26, 4426-4431

20

Makrigiorgos, G.M., Chakrabarti, S., Zhang, Y., Kaur, M. & Price, B. D. (2002) PCR-based amplification method retaining the quantitative difference between two complex genomes. *Nat Biotechnol.* 20, 936 – 939

25

Spirin, KS, Ljubimov, AV, Castellon R, Wiedoeft, O, Marano, M, Sheppard D, Kenney, MC, Brown DJ : (1999) Analysis of gene expression in human bullous keratopathy corneas containing limiting amounts of RNA. *Investigative Ophthalmology & Visual Science*, 40, 3108-3115

30

Gonzales P, Zigler, Jr JS, Epstein DL, and Borrás T (1999) Identification and isolation of differentially expressed genes from very small tissue samples. *Biotechniques* 26, 884-892



Vernon, SD, Unger, ER, Rajeevan M, Dimulesco IM, Nisenbaum R and Campbell CE (2000) Reproducibility of alternative probe synthesis approaches for gene expression profiling with arrays. *J. Mol. Diag.* 2, 124-127

5

Livesey, FJ, Furukawa, MA, Steffen, MA, Church, GM and Cerko, CL (2000) Microarray analysis of the transcriptional network controlled by the photoreceptor homeobox gene. *Crx Curr. Biol.* 10, 301-310

- 10 Zhumabayeva, B., Diatchenko, L., Chenchik, A., and Siebert, P.D. (2001) Use of SMART<sup>TM</sup>-generated cDNA for gene expression studies in multiple human tumours. *Biotechniques* 30, 158-163

- Fink, L, Kohlhoff, S, Stein, MM, Hanze J, Weissmann, N, Rose, F, Akkayagil, E,  
15 Manz, D, Grimminger F, Seeger, W and Bohle, RM (2002) cDNA array hybridization after laser-assisted microdissection form nonneoplastic tissue. *Am. J. Path.* 160 : 81-90

- Clark, J.M. (1988). Novel non-templated nucleotide addition reactions catalyzed by  
20 prokaryotic and eukaryotic DNA polymerases. *Nucleic Acids Res.* 16, 9677-9686

---

Hu, W.S. and Temin, H.M. (1990) Retroviral recombination and reverse transcriptase. *Science* 250, 1227-1233

- 25 Chamberlin and Ryan, in *The Enzymes*, ed. P. Boyer (Academic Press, New York) pp. 87-108 (1982).

Rosenberg et al., (1987) *Gene* 56: 125-135

- 30 Duguid et al., *Proc. Natl. Acad. Sci. USA* 85: 5738-5742 (1988)

Sive & St. John, (1988) *Nucl. Acids Res.* 16, 10937

Chirgwin, J.M., Przybyla, A.E., McDonald, R.J., and Rutter, W.J. et al, (1979) Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. *Biochemistry* 18, 5294-5299

- 5 Chomczynski, P. & Sacchi, N. (1987). Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal. Biochem.* 162, 156-159.

10 Sambrook, J., Fritsch, E. F. & Maniatis, T. (1989) *Molecular Cloning: A Laboratory Manual*, Second Edition (Cold Spring Harbor Laboratory, NY)

Farrell, Jr., R. E. (1993) *RNA Methodologies—A Lab Guide for Isolation and Characterization*  
(Academic Press, San Diego, CA)

15

Huang, L, Sitarman K, Gallego, A, Rashtchian, A. (2000) A new highly sensitive two-step RT-PCR system, *Focus* 22, 6-7

20 Baugh, L.R., Hill, A.A., Brown, E.L., and Hunter, C.P. (2001) Quantitative analysis of mRNA amplification by in vitro transcription. *Nucleic Acids Res.* 29, e29

Barnes, W. M. (1994) PCR amplification of up to 35-kb DNA with high fidelity and high yield from bacteriophage templates. *Proc. Natl. Acad. Sci. USA* 91, 2216-2220.

- 25 Kellogg, D. E., Rybalkin, I., Chen, S., Mukhamedova, N., Vlasik, T., Siebert, P. & Chenchik, A. (1994) TaqStart Antibody: Hotstart PCR facilitated by a neutralizing monoclonal antibody directed against Taq DNA polymerase. *BioTechniques* 16, 1134-1137.

CLAIMS

1. A cDNA-RNA hybrid comprising a first strand cDNA synthesis substantially hybridised to RNA wherein the cDNA comprises an amplifier sequence and an RNA  
5 annealing region operably linked to an RNA polymerase promoter, and wherein at least one non-templated nucleotide at the 3' end of the first strand cDNA is hybridised to a template switching oligonucleotide.
  2. A cDNA-RNA hybrid according to claim 1 wherein the RNA is mRNA.
  - 10 3. A cDNA-RNA hybrid according to claim 1 or claim 2 wherein the RNA polymerase promoter is a bacteriophage promoter.
  4. A cDNA-RNA hybrid according to claim 3 wherein the bacteriophage  
15 promoter is selected from the group consisting of T7, T3 and SP6.
  5. A cDNA-RNA hybrid according to claim any one of the preceding claims wherein the RNA annealing region comprises poly (dT).
  - 20 6. A cDNA-RNA hybrid according to claim 5 wherein the oligo(T) region is from about 10 to about 30 T residues in length.
- 
7. A cDNA-RNA hybrid according to any one of the preceding claims wherein the 3' end of the RNA annealing region comprises a VN clamp, wherein V is A, G  
25 or C and N is A, G, C or T.
  8. A cDNA-mRNA hybrid according to any one of the preceding claims wherein at least one non-templated nucleotide at the 3' end of the first strand cDNA synthesis is deoxycytidine.
  - 30 9. A cDNA-mRNA hybrid according to any one of the preceding claims wherein at least three non-templated nucleotide at the 3' end of the first strand cDNA synthesis are hybridised to a template switching oligonucleotide.

10. A cDNA-mRNA hybrid according to any one of the preceding claims wherein at least three of the non-templated nucleotides at the 3' end of the first strand cDNA synthesis are deoxycytidine nucleotides.

5

11. A cDNA-mRNA hybrid according to any one of the preceding claims wherein the template switching oligonucleotide has at least three guanine residues at its 3' end.

10 12. A cDNA-mRNA hybrid according to any one of the preceding claims wherein the amplifier sequence, the amplification primer and the template switching oligonucleotide contain the same sequence.

13. A cDNA-mRNA hybrid according to any one of the preceding claims  
15 wherein the 3' end of the first strand cDNA synthesis is extended such that it is substantially complementary to the template switching oligonucleotide.

14. A cDNA-mRNA hybrid according to any one of the preceding claims wherein the first strand cDNA synthesis is synthesised by a reverse transcriptase.

20

15. A cDNA-mRNA hybrid according to claim 14 wherein the reverse transcriptase lacks RNaseH activity but retains wild-type polymerase activity.

16. A cDNA-mRNA hybrid according to claim 14 or claim 15 wherein the  
25 reverse transcriptase is a Moloney Murine Leukemia virus (MMLV) reverse transcriptase or a mutant thereof.

17. A cDNA-mRNA hybrid according to any one of claims 14 to 16 wherein the reverse transcriptase is PowerScript<sup>TM</sup> Reverse Transcriptase (BD Biosciences  
30 Clontech).

18. A method for amplifying RNA in a sample comprising the steps of:

- (a) providing a cDNA synthesis oligonucleotide comprising an amplifier sequence and an RNA annealing region operably linked to an RNA polymerase promoter;
- 5 (b) annealing the RNA annealing region of the cDNA synthesis oligonucleotide to RNA under suitable conditions to produce a cDNA-RNA complex;
- (c) incubating said cDNA-RNA complex under conditions which permit template-dependent extension of the cDNA synthesis oligonucleotide to generate an  
10 cDNA-RNA hybrid;
- (d) contacting said cDNA-mRNA hybrid with a template switching oligonucleotide under conditions which permit template dependent extension of said cDNA, such that the 3' end of the cDNA comprises a sequence complementary to  
15 said template switching oligonucleotide;
- (e) providing an amplification primer under conditions to generate double stranded amplification products corresponding substantially to the first strand cDNA synthesis, such that the cDNA amplification products comprise a double stranded  
20 RNA polymerase promoter; and
- 
- (f) incubating said cDNA amplification products comprising said double stranded RNA polymerase promoter under conditions that permit *in vitro* transcription to generate amplified RNA.  
25
19. A method according to claim 18 wherein said cDNA-RNA hybrid is incubated with a reverse transcriptase that adds at least one deoxycytidine residue to the 3' end of the first strand cDNA synthesis.
- 30 20. A method according to claim 18 or claim 19 wherein at least three non-templated nucleotide at the 3' end of the first strand cDNA synthesis are hybridised to a template switching oligonucleotide.

21. A method according to any one of claims 18 to 20 wherein the at least three of the non-templated nucleotides at the 3' end of the first strand cDNA synthesis are deoxycytidine residues.

5 22. A method according to any one of claims 18 to 21 wherein the reverse transcriptase lacks RNaseH activity but retains wild-type polymerase activity.

23. A method according to any one of claims 18 to 22 wherein the reverse transcriptase is a Moloney Murine Leukemia virus (MMLV) reverse transcriptase or  
10 a mutant thereof.

24. A method according to any one of claims 18 to 23 wherein the reverse transcriptase is PowerScript™ Reverse Transcriptase (BD Biosciences Clontech).

15 25. A method according to any one of claims 18 to 24 wherein said template switching oligonucleotide comprises at least three ribonucleotide residues.

26. A method according to any one of claims 18 to 25 wherein said template switching oligonucleotide comprises at least three guanine residues.

20

27. A method according to any one of claims 18 to 26 wherein said amplification primer has the same sequence as the amplifier sequence of said cDNA synthesis oligonucleotide.

25 28. A method according to any one of claims 18 to 27 wherein the reaction comprises 1 mM dNTPs.

29. A method according to any one of claims 18 to 28 wherein the double stranded amplification products are obtained by PCR.

30

30. A method according to any one of claims 18 to 29 wherein the cDNA synthesis oligonucleotide and the PCR primer have the same concentration

31. A method according to any one claims 18 to 30 wherein PCR amplification is performed using Advantage® 2 Polymerase mix (BD Biosciences Clontech).

32. A method according to any one of claims 18 to 31 wherein the optimum number of cycles to generate the double stranded amplification products is determined by a method comprising the steps of:

- (a) providing a plurality of samples with a known amount of RNA;
- 10 (b) performing amplification for a defined number of cycles on the plurality of samples;
- (c) purifying the double stranded amplification products;
- 15 (d) providing for the *in vitro* transcription of the purified amplification products; and
- (e) determining the number of amplification cycles that results in the minimum amount of amplified RNA that is required.

20

33. A method according to any one of claims 18 to 32 wherein the RNA sample is a clinical sample selected from the group consisting of a biopsy, a microdissected tissue; a fine needle aspirate, a flow-sorted cell, a laser captured microdissected cell or a single cell.

25

34. A method for preparing an expression library of a cell or a cell population comprising the steps of:

- (a) providing a cDNA synthesis oligonucleotide comprising an amplifier sequence and an RNA annealing region operably linked to an RNA polymerase promoter

30

(b) contacting said cDNA synthesis oligonucleotide with a population of mRNAs from said cell or cell population under conditions to allow hybridisation of said cDNA synthesis oligonucleotide to mRNA to produce a cDNA-mRNA complex;

5

(c) incubating said cDNA-mRNA complex under conditions which permit template-dependent extension of said cDNA synthesis oligonucleotide to generate a cDNA-mRNA hybrid;

10 (d) contacting said cDNA-mRNA hybrid with a template switching oligonucleotide under conditions which permit template dependent extension of said cDNA, such that the 3' end of the cDNA of the cDNA-mRNA hybrid comprises a sequence complementary to said template switching oligonucleotide;

15 (e) contacting an amplification primer with said cDNA-mRNA hybrid under conditions that generate double stranded amplification products corresponding to the first strand cDNA synthesis, such that the double stranded cDNA amplification products comprise a double stranded RNA polymerase promoter; and

20 (f) incubating said double stranded cDNA amplification products comprising said double stranded RNA polymerase promoter under conditions that permit *in vitro* transcription to generate amplified RNA.

35. A method of preparing a cDNA library from a collection of mRNA  
25 molecules comprising the steps of:

(a) providing a cDNA synthesis oligonucleotide comprising an amplifier sequence and an RNA annealing region operably linked to an RNA polymerase promoter;

30

(b) contacting said cDNA synthesis oligonucleotide with the collection of mRNAs under conditions to allow annealing of said cDNA synthesis oligonucleotide to mRNA produce a cDNA-mRNA complex;



(c) incubating said cDNA-mRNA complex under conditions which permit template-dependent extension of said cDNA synthesis oligonucleotide to generate a cDNA-mRNA hybrid;

5

(d) contacting said cDNA-mRNA hybrid with a template switching oligonucleotide under conditions which permit template dependent extension of said cDNA of said hybrid, such that the 3' end of the cDNA of the cDNA-mRNA hybrid comprises a sequence complementary to said template switching oligonucleotide;

10

(e) contacting a PCR primer with said cDNA-mRNA hybrid under conditions that generate double stranded amplification products corresponding to the first strand cDNA synthesis, such that the double stranded cDNA amplification products comprise a double stranded RNA polymerase promoter;

15

(f) incubating said double stranded cDNA amplification products comprising said double stranded RNA polymerase promoter under conditions that permit *in vitro* transcription to generate amplified RNA; and

20 (g) preparing a cDNA library from the amplified RNA.

---

36. A method for performing subtractive hybridisation comprising the steps of:

(a) providing a cDNA synthesis oligonucleotide comprising an amplifier  
25 sequence and an RNA annealing region operably linked to an RNA polymerase promoter;

(b) contacting the cDNA synthesis oligonucleotide with a collection of mRNAs under conditions to allow annealing of said cDNA synthesis oligonucleotide to  
30 mRNA in said RNA sample to produce a cDNA-mRNA complex;

- (c) incubating said cDNA-mRNA hybrid with enzyme, dNTPs and buffer under conditions which permit template-dependent extension of said cDNA synthesis oligonucleotide to generate a cDNA-mRNA hybrid;
- 5 (d) contacting said cDNA-mRNA hybrid with a template switching oligonucleotide under conditions which permit template dependent extension of said cDNA of said hybrid, such that the 3' end of the cDNA of the cDNA-mRNA hybrid comprises a sequence complementary to said template switching oligonucleotide;
- 10 (e) contacting an amplification primer with said cDNA-mRNA hybrid under conditions to generate double stranded amplification products corresponding to the first stand cDNA synthesis, such that the double stranded cDNA amplification products comprise a double stranded RNA polymerase promoter;
- 15 (f) incubating said double stranded cDNA amplification products comprising said double stranded RNA polymerase promoter under conditions that permit *in vitro* transcription to generate amplified RNA;
- (g) contacting said amplified RNA with a single stranded nucleic acid  
20 population in the opposite sense to said amplified RNA;
- (h) providing for the hybridisation of the sequences present in the amplified RNA and the single stranded nucleic acid population; and
- 25 (i) isolating the nucleic acid population that remains single stranded.
37. A method for detecting the expression of a gene of interest comprising the steps of:
- 30 (a) providing a cDNA synthesis oligonucleotide comprising an amplifier sequence and an RNA annealing region operably linked to an RNA polymerase promoter, wherein the RNA annealing region comprises a sequence that is substantially homologous to the mRNA expressed by the gene of interest;

(b) contacting said cDNA synthesis oligonucleotide with a population of mRNAs in a cell or cell population under conditions to allow annealing of said cDNA synthesis oligonucleotide to mRNA to produce a cDNA-mRNA complex;

5

(c) incubating said cDNA-mRNA hybrid under conditions which permit template-dependent extension of said cDNA synthesis oligonucleotide to generate a cDNA-mRNA hybrid;

10 (d) contacting said cDNA-mRNA hybrid with a template switching oligonucleotide under conditions which permit template dependent extension of said cDNA of said hybrid, such that the 3' end of the cDNA of the cDNA-mRNA hybrid comprises a sequence complementary to said template switching oligonucleotide;

15 (e) contacting an amplification primer with said cDNA-mRNA hybrid under conditions to generate double stranded amplification products corresponding to the first strand cDNA synthesis, such that the double stranded cDNA amplification products comprise a double stranded RNA polymerase promoter;

20 (f) incubating said double stranded cDNA amplification products comprising said double stranded RNA polymerase promoter under conditions that permit *in vitro* transcription to generate amplified RNA; and

---

(g) determining the presence or absence of amplified RNA, which amplified  
25 RNA is complementary to mRNA corresponding to the gene of interest.

38. Amplified RNA obtainable by the method according to any one of claims 18 to 33.

30 39. An expression library obtainable by the method according to claim 34.

40. A cDNA library obtainable by the method according to claim 35.

41. Use of a cDNA-mRNA hybrid according to any one of claims 1-17 in the amplification of RNA.

42. Use of a cDNA-mRNA hybrid according to any one of claims 1-17 in the  
5 preparation of a cDNA library.

43. Use of a cDNA-mRNA hybrid according to any one of claims 1-17 in subtractive hybridisation.

10 44. Use of a cDNA-mRNA hybrid according to any one of claims 1-17 for measuring gene expression.

45. The use according to claim 44 wherein the gene expression is measured using a microarray.

15

46. A kit for the amplification of RNA in a sample comprising:

(a) a cDNA synthesis oligonucleotide comprising an amplifier sequence and an RNA annealing region operably linked to an RNA polymerase promoter;

20

(b) a template switching oligonucleotide that has substantially the same sequence as the amplifier sequence; and

(c) an amplification primer that has substantially the same sequence as the  
25 template switching oligonucleotide.

47. The kit according to claim 46, wherein the kit further comprises in a separate container a reverse transcriptase.

30 48. The kit according to claim 47 wherein the reverse transcriptase lacks RNaseH activity but retains wild-type polymerase activity.

49. The kit according to claim 47 or claim 48 wherein the reverse transcriptase is a Moloney Murine Leukemia virus (MMLV) reverse transcriptase or a mutant thereof.

5 50. The kit according to any one of claims claim 47 to 49 wherein the reverse transcriptase is PowerScript<sup>TM</sup> Reverse Transcriptase (BD Biosciences Clontech).

51. The kit according to any one of claims 47 to 50, wherein the kit further comprises in a separate container an RNA polymerase specific to the RNA  
10 polymerase promoter of the cDNA synthesis oligonucleotide.

52. The kit according to any one of claims claim 47 to 51, wherein the RNA polymerase promoter is selected from a T7, T3 or SP6 RNA polymerase promoter.

15 53. The kit according to any one of claims 47 to 52, wherein the kit further comprises an amplification buffer and one or more amplification enzymes.


54. The kit according to claim 53, wherein the amplification buffer and the amplification enzyme(s) are PCR amplification buffer and PCR amplification  
20 enzyme(s).

---

55. The kit according to any one of claims 47 to 54, wherein the kit further comprises a control nucleic acid.

Figure 1

1/14




**Figure 2****2/14**probe synthesis yields ( $\mu\text{g}$  cRNA)

Figure 3

3/14








Figure 4

4/14

HSAC07/X00351



HUMGAPDH/M33197



Percentage of Present Calls for (U133A)





Figure 5

5/14



## Figure 6

6/14

5





Figure 7

7/14

5



10

15

20

Figure 8

8/14

5




Figure 9

9/14





Figure 10

10/14

## 70 clusters - all genes



## 70 clusters - genes changing &gt;2 fold





Figure 11

11/14

## examples





12/14






Figure 13

13/14



14/14



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**